var title_f33_2_33824="Diphenhydramine: Drug information";
var content_f33_2_33824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphenhydramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/33/7705?source=see_link\">",
"       Diphenhydramine (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1269?source=see_link\">",
"       Diphenhydramine (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9369 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33824=[""].join("\n");
var outline_f33_2_33824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/33/7705?source=related_link\">",
"      Diphenhydramine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/15/1269?source=related_link\">",
"      Diphenhydramine (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_2_33825="de Quervain tenosynovitis location";
var content_f33_2_33825=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    de Quervain tenosynovitis location",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 312px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    De Quervain's tenosynovitis refers to entrapment tendonitis or tenosynovitis of the abductor pollicis longus and extensor pollicis brevis tendons at the styloid process of the radius.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Blake Boggess, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33825=[""].join("\n");
var outline_f33_2_33825=null;
var title_f33_2_33826="Contents: Infections and vaccines";
var content_f33_2_33826=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?18/22/18798\">",
"       Patient Information",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Infections and vaccines",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Infections and vaccines",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Adenovirus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/7/13426\">",
"           Patient information: Adenovirus infections (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Animal borne disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/15/22770\">",
"           Patient information: Animal bites (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/32/28161\">",
"           Patient information: Animal bites (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/40/35457\">",
"           Patient information: Cat scratch disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/40/37505\">",
"           Patient information: Leptospirosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/61/11217\">",
"           Patient information: Psittacosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/55/30578\">",
"           Patient information: Rabies (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/23/2418\">",
"           Patient information: Rabies (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Antibiotics",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/37/31314\">",
"           Patient information: Antibiotics before procedures (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/12/12483\">",
"           Patient information: What you should know about antibiotics (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Body fluid exposures",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/31/18931\">",
"           Patient information: Blood or body fluid exposure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/35/31282\">",
"           Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Central line infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/33/35345\">",
"           Patient information: Central line infections (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chickenpox and shingles",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/57/27538\">",
"           Patient information: Chickenpox (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/40/2691\">",
"           Patient information: Chickenpox prevention and treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/12/13507\">",
"           Patient information: Shingles (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/0/14338\">",
"           Patient information: Shingles (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Chronic fatigue syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/11/42161\">",
"           Patient information: Chronic fatigue syndrome (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/47/4850\">",
"           Patient information: Chronic fatigue syndrome (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Creutzfeldt-Jakob disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/50/25378\">",
"           Patient information: Creutzfeldt-Jakob disease (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cytomegalovirus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/10/19618\">",
"           Patient information: Cytomegalovirus (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diarrhea",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/29/36308\">",
"           Patient information: Acute diarrhea in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/1/27\">",
"           Patient information: Acute diarrhea in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/47/28402\">",
"           Patient information: Antibiotic-associated diarrhea (C. difficile infection) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/52/19267\">",
"           Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/14/7395\">",
"           Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/5/9299\">",
"           Patient information: Diarrhea in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/34/34338\">",
"           Patient information: Diarrhea in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/1/21522\">",
"           Patient information: Giardia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/26/11684\">",
"           Patient information: Lactose intolerance (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         E. coli",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/63/31730\">",
"           Patient information: E. coli (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Ear infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/16/15619\">",
"           Patient information: Ear infections (otitis media) in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/12/26816\">",
"           Patient information: External otitis (including swimmer's ear) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/2/15394\">",
"           Patient information: Outer ear infection (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Endocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/48/26370\">",
"           Patient information: Endocarditis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Enterococci",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/19/39217\">",
"           Patient information: Vancomycin-resistant enterococci (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eye infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/51/20274\">",
"           Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/6/26721\">",
"           Patient information: Conjunctivitis (pinkeye) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/37/24145\">",
"           Patient information: Orbital cellulitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Flu",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/58/6050\">",
"           Patient information: Bird flu (avian influenza) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/47/33522\">",
"           Patient information: Flu (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/12/39105\">",
"           Patient information: Influenza prevention (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/12/35013\">",
"           Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Food poisoning",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/42/2723\">",
"           Patient information: Campylobacter infection (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/63/31730\">",
"           Patient information: E. coli (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/22/10595\">",
"           Patient information: Food poisoning (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/30/29156\">",
"           Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/29/28114\">",
"           Patient information: Listeria (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/57/28562\">",
"           Patient information: Nausea and vomiting in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/13/27858\">",
"           Patient information: Rotavirus infection (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/31/27122\">",
"           Patient information: Salmonellosis (Salmonella) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/26/38305\">",
"           Patient information: Typhoid fever (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/3/9267\">",
"           Patient information: Viral gastroenteritis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fungal infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/6/31842\">",
"           Patient information: Chronic pulmonary aspergillosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/6/36962\">",
"           Patient information: Fungal meningitis and septic arthritis outbreak (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/1/42001\">",
"           Patient information: Fungal nail infections (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/5/13393\">",
"           Patient information: Histoplasmosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/23/12658\">",
"           Patient information: Invasive aspergillosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/54/27489\">",
"           Patient information: Thrush (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/19/13617\">",
"           Patient information: Valley Fever (coccidioidomycosis) (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Gangrene",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/13/210\">",
"           Patient information: Gangrene (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hepatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/31/18931\">",
"           Patient information: Blood or body fluid exposure (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/61/22483\">",
"           Patient information: Hepatitis A (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/46/41698\">",
"           Patient information: Hepatitis A (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/45/31447\">",
"           Patient information: Hepatitis B (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/41/26258\">",
"           Patient information: Hepatitis B (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/4/17478\">",
"           Patient information: Hepatitis C (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/39/32370\">",
"           Patient information: Hepatitis C (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/22/4451\">",
"           Patient information: Latest medicines for hepatitis C (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/35/31282\">",
"           Patient information: Preventing HIV after unprotected sex or needle-sharing (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/35/30258\">",
"           Patient information: Treatment for hepatitis C (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/45/1746\">",
"           Patient information: Vaccines when you have hepatitis C (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Insect borne disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/27/16818\">",
"           Patient information: Dengue fever (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/40/30338\">",
"           Patient information: Lyme disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/0/27649\">",
"           Patient information: Lyme disease prevention (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/17/32022\">",
"           Patient information: Lyme disease symptoms and diagnosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/41/5778\">",
"           Patient information: Lyme disease treatment (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/47/3826\">",
"           Patient information: Malaria (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/2/22562\">",
"           Patient information: Rocky Mountain spotted fever (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/19/16690\">",
"           Patient information: West Nile virus infection (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/10/13474\">",
"           Patient information: What to do after a tick bite to prevent Lyme disease (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Joint infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/6/36962\">",
"           Patient information: Fungal meningitis and septic arthritis outbreak (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/21/18769\">",
"           Patient information: Joint infection (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/63/17393\">",
"           Patient information: Septic arthritis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Measles, Mumps, Rubella",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/56/2947\">",
"           Patient information: Measles (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/24/11650\">",
"           Patient information: Mumps (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/10/14499\">",
"           Patient information: Rubella (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Meningitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/35/16946\">",
"           Patient information: Aseptic meningitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/1/31762\">",
"           Patient information: Bacterial meningitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/6/36962\">",
"           Patient information: Fungal meningitis and septic arthritis outbreak (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/48/1796\">",
"           Patient information: Meningitis in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/43/3763\">",
"           Patient information: Meningitis in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/34/28194\">",
"           Patient information: Viral meningitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mononucleosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/11/176\">",
"           Patient information: Infectious mononucleosis (mono) in adults and adolescents (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/33/41489\">",
"           Patient information: Mono, the ���������kissing disease��������� (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Osteomyelitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/15/15601\">",
"           Patient information: Osteomyelitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parasites",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/24/6530\">",
"           Patient information: Cryptosporidiosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/0/28673\">",
"           Patient information: Giardia (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/1/21522\">",
"           Patient information: Giardia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/33/9746\">",
"           Patient information: Pinworms (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parotitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/14/5346\">",
"           Patient information: Parotitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parvovirus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/5/13394\">",
"           Patient information: Erythema infectiosum (fifth disease) (The Basics )",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polio",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/57/8082\">",
"           Patient information: Poliomyelitis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pregnancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/52/43843\">",
"           Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/39/33395\">",
"           Patient information: Avoiding infections in pregnancy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/42/42657\">",
"           Patient information: Group B streptococcal disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/63/11248\">",
"           Patient information: Group B streptococcus and pregnancy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/29/7635\">",
"           Patient information: HIV and pregnancy (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Respiratory tract infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/28/24002\">",
"           Patient information: Acute bronchitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/57/9106\">",
"           Patient information: Acute bronchitis in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/34/13858\">",
"           Patient information: Aspiration pneumonia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/10/39074\">",
"           Patient information: Bronchiolitis (and RSV) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/19/27958\">",
"           Patient information: Bronchiolitis (and RSV) in infants and children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?12/29/12754\">",
"           Patient information: Community-acquired pneumonia in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/0/43011\">",
"           Patient information: Cough in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/7/13427\">",
"           Patient information: Cough in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/55/18291\">",
"           Patient information: Cough, runny nose, and the common cold (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/43/22195\">",
"           Patient information: Coughing up blood (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/5/13393\">",
"           Patient information: Histoplasmosis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/1/19474\">",
"           Patient information: Hospital-acquired pneumonia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/44/14019\">",
"           Patient information: Mycoplasma pneumonia in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/24/7554\">",
"           Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?29/38/30308\">",
"           Patient information: Pneumonia in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/18/36130\">",
"           Patient information: Pneumonia in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/17/14611\">",
"           Patient information: Pneumonia in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/57/14225\">",
"           Patient information: Pneumonia prevention (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/42/4770\">",
"           Patient information: Severe Acute Respiratory Syndrome (SARS) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/11/44210\">",
"           Patient information: The common cold in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/44/40643\">",
"           Patient information: The common cold in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/19/13617\">",
"           Patient information: Valley Fever (coccidioidomycosis) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/38/36450\">",
"           Patient information: Whooping cough (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sepsis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/50/33569\">",
"           Patient information: Sepsis in adults (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sexually transmitted infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/4/28738\">",
"           Patient information: Care after rape or sexual assault (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/30/1509\">",
"           Patient information: Care after sexual assault (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/14/24802\">",
"           Patient information: Chlamydia (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/52/23362\">",
"           Patient information: Chlamydia and gonorrhea (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/37/27217\">",
"           Patient information: Congenital syphilis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/3/36916\">",
"           Patient information: Genital herpes (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/25/21906\">",
"           Patient information: Genital herpes (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/13/16594\">",
"           Patient information: Genital warts (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/60/4035\">",
"           Patient information: Genital warts in women (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/44/1730\">",
"           Patient information: Gonorrhea (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/45/38610\">",
"           Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/22/5475\">",
"           Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/14/26850\">",
"           Patient information: Pelvic inflammatory disease (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/12/27843\">",
"           Patient information: Pubic lice (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/57/1940\">",
"           Patient information: Screening for sexually transmitted diseases (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/61/10195\">",
"           Patient information: Syphilis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/62/8162\">",
"           Patient information: Trichomoniasis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/44/4803\">",
"           Patient information: Urethritis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sinusitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/13/37073\">",
"           Patient information: Acute sinusitis (sinus infection) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/58/42915\">",
"           Patient information: Chronic rhinosinusitis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/53/17234\">",
"           Patient information: Sinusitis in adults (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Skin infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/63/20465\">",
"           Patient information: Boil (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/23/4466\">",
"           Patient information: Cellulitis and erysipelas (skin infections) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?4/24/4482\">",
"           Patient information: Cold sores (oral herpes) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/38/23137\">",
"           Patient information: Folliculitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/55/8048\">",
"           Patient information: Impetigo (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/18/26913\">",
"           Patient information: Impetigo (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/4/22595\">",
"           Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/47/31473\">",
"           Patient information: Methicillin-resistant Staphylococcus aureus (MRSA) (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/35/43583\">",
"           Patient information: Molluscum contagiosum (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/25/23953\">",
"           Patient information: Paronychia (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?15/62/16353\">",
"           Patient information: Pilonidal cyst (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/55/15217\">",
"           Patient information: Skin and soft tissue infection (cellulitis) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/60/15297\">",
"           Patient information: Tinea nigra (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/47/24305\">",
"           Patient information: Tinea versicolor (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sore throat",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/59/40881\">",
"           Patient information: Scarlet fever (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/15/36082\">",
"           Patient information: Sore throat in adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/57/914\">",
"           Patient information: Sore throat in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/26/28066\">",
"           Patient information: Sore throat in children (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?8/34/8738\">",
"           Patient information: Strep throat in children (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Splenectomy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/24/18818\">",
"           Patient information: Preventing severe infection after splenectomy (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tetanus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/34/31266\">",
"           Patient information: Tetanus (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Travel precautions",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/27/16818\">",
"           Patient information: Dengue fever (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/2/16421\">",
"           Patient information: General travel advice (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/47/3826\">",
"           Patient information: Malaria (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/3/20530\">",
"           Patient information: Travelers��������� diarrhea (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/44/21187\">",
"           Patient information: Vaccines for travel (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tuberculosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/35/39475\">",
"           Patient information: Tuberculosis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?24/57/25489\">",
"           Patient information: Tuberculosis (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urinary tract infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/25/28048\">",
"           Patient information: Kidney infection (pyelonephritis) (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/18/32036\">",
"           Patient information: Urinary tract infections in adolescents and adults (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/47/20210\">",
"           Patient information: Urinary tract infections in adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/58/38818\">",
"           Patient information: Urinary tract infections in children (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/38/10850\">",
"           Patient information: Urinary tract infections in children (The Basics)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vaccines",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/25/39318\">",
"           Patient information: Adult vaccines (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?37/45/38610\">",
"           Patient information: Human papillomavirus (HPV) vaccine (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?5/22/5475\">",
"           Patient information: Human papillomavirus (HPV) vaccine (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?2/56/2947\">",
"           Patient information: Measles (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/24/11650\">",
"           Patient information: Mumps (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/57/8082\">",
"           Patient information: Poliomyelitis (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/10/14499\">",
"           Patient information: Rubella (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?13/12/13507\">",
"           Patient information: Shingles (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/0/14338\">",
"           Patient information: Shingles (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?32/61/33746\">",
"           Patient information: Tdap vaccine (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/34/31266\">",
"           Patient information: Tetanus (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/7/17522\">",
"           Patient information: Vaccination during pregnancy (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?11/48/12035\">",
"           Patient information: Vaccines (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?7/52/8003\">",
"           Patient information: Vaccines and pregnancy (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/4/23619\">",
"           Patient information: Vaccines for adults (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?27/22/28003\">",
"           Patient information: Vaccines for babies and children age 0 to 6 years (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/18/37156\">",
"           Patient information: Vaccines for children age 7 to 18 years (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/7/18547\">",
"           Patient information: Vaccines for children age 7 to 18 years (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/36/42566\">",
"           Patient information: Vaccines for infants and children age 0 to 6 years (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/44/21187\">",
"           Patient information: Vaccines for travel (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/38/36450\">",
"           Patient information: Whooping cough (The Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?17/42/18084\">",
"           Patient information: Why does my child need vaccines? (Beyond the Basics)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-413F0B43D8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f33_2_33826=[""].join("\n");
var outline_f33_2_33826=null;
var title_f33_2_33827="Dimethyl sulfoxide: Patient drug information";
var content_f33_2_33827=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dimethyl sulfoxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33123?source=see_link\">",
"     see \"Dimethyl sulfoxide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rimso-50&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dimethyl Sulfoxide Irrigation, USP;",
"     </li>",
"     <li>",
"      Kemsol&reg;;",
"     </li>",
"     <li>",
"      Rimso-50&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10017609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain, swelling, and irritation of the bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701957",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dimethyl sulfoxide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697351",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bladder cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697938",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body odor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694770",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. It is for use as a bladder rinse only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11938 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-7B5B02C4AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33827=[""].join("\n");
var outline_f33_2_33827=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160865\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160866\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017609\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017611\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017610\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017615\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017616\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017618\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017613\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017614\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017619\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017620\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/22/33123?source=related_link\">",
"      Dimethyl sulfoxide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_2_33828="Coxa vara";
var content_f33_2_33828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Normal femur versus coxa vara",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 525px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal femur (left) versus coxa vara (right). Coxa vara is defined by an angle of less than 120 degrees between the femoral neck and shaft. Coxa vara deformity elevates the greater trochanter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: LifeART. Copyright &copy; 2011. Lippincott Williams &amp; Wilkins. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33828=[""].join("\n");
var outline_f33_2_33828=null;
var title_f33_2_33829="Certolizumab pegol for treatment of Crohn's disease in adults";
var content_f33_2_33829=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Certolizumab pegol for treatment of Crohn's disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33829/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33829/contributors\">",
"     Joshua R Korzenik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33829/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33829/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33829/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33829/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/2/33829/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     Certolizumab pegol",
"    </a>",
"    (Cimzia&reg;) is a humanized monoclonal antibody Fab fragment linked to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    that neutralizes tumor necrosis factor (TNF). The polyethylene glycol increases its plasma half-life and reduces the requirement for frequent dosing, possibly reducing immunogenicity as well. The drug has higher binding affinity for TNF than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    based upon an in vitro study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike anti-TNF monoclonal antibodies,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    does not have a Fc region; as a result, it does not activate the complement pathway, result in cell- or antibody-mediated cytotoxicity, or induce apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical significance of these differences is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     Certolizumab pegol",
"    </a>",
"    received approval from the US Food and Drug Administration in 2008 for treatment and maintenance of response in adults with moderate to severe Crohn's disease who had an inadequate response to conventional therapy. The drug is also approved in Switzerland, but it has not been approved by the European Medicines Agency and is therefore not widely available in Europe. The manufacturer is also seeking approval for the treatment of rheumatoid arthritis and psoriasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase 2 dose-finding study led to the selection of a 400 mg dose for later clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/2\">",
"     2",
"    </a>",
"    ]. Approval for Crohn's disease was based upon two placebo-controlled trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the trials (PRECiSE 1) included 662 patients with moderate-to-severe active Crohn's disease who were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    (400 mg) or placebo at weeks 0, 2, 4 and then every 4 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/3\">",
"     3",
"    </a>",
"    ]. The primary endpoints were induction of a response at week 6 and a response at both weeks 6 and 26. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Response rates at weeks 6 and 26 were significantly higher in the certolizumab group (35 versus 27 and 23 versus 16 percent, respectively). Response rates were increased in a subset of patients with a baseline serum CRP level of at least 10",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"     </li>",
"     <li>",
"      However, rates of remission did not differ significantly between the groups or in the subset with higher CRP levels.",
"     </li>",
"     <li>",
"      At week 26, the rate of maintenance of response among those who initially responded was not different between the active treatment and placebo patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The second trial (PRECiSE 2) evaluated the efficacy of maintenance therapy in 668 patients with moderate-to-severe Crohn's disease who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    (400 mg) for six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/4\">",
"     4",
"    </a>",
"    ]. The 428 patients (64 percent) who responded were randomly assigned to continue treatment (continuous therapy) or receive placebo (drug interruption) until a total of 26 weeks. Maintenance of response was significantly higher in the active treatment group (63 versus 36 percent) at week 26.",
"   </p>",
"   <p>",
"    In a third open-label extension trial (PRECiSE 3), patients who completed PRECiSE 2 were eligible to receive treatment with certolizumab every four weeks for up to five years. Remission rates were maintained at week 80 in 63 percent of the patients who had been in remission at week 26 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A fourth trial (PRECiSE 4) evaluated the efficacy of reintroducing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    in patients with active Crohn's disease who had responded to induction therapy and then relapsed during continuous or interrupted therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/7\">",
"     7",
"    </a>",
"    ]. Patients in PRECiSE 2 who relapsed while on continuous therapy were eligible to receive treatment with a single extra dose, and patients who relapsed after drug interruption received treatment at weeks 0, 2, 4, and then every 4 weeks. Response rates at week 4 were 63 percent in those who relapsed after continuous therapy and 65 percent after drug interruption. Response was maintained through week 52 in these responders (55 and 59 percent, respectively).",
"   </p>",
"   <p>",
"    Subanalyses of the PRECiSE trials have shown clinically meaningful and significant improvement in the quality of life with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a meta-analysis of four studies failed to demonstrate a benefit of certolizumab for the induction of remission compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Patients previously treated with infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;A post-hoc analysis from PRECiSE 2 suggested that individuals responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    whether or not they had previously received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . However, there was a significantly higher rate of response in those who had not previously received infliximab (64 versus 39 percent with placebo) compared with those who had previously received infliximab (44 versus 25 percent with placebo).",
"   </p>",
"   <p>",
"    The same rate of response was noted in the WELCOME Study, which evaluated the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    in 539 patients who had previously responded to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    and subsequently lost response or became intolerant to continued therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/11\">",
"     11",
"    </a>",
"    ]. During an open-label period, patients were given certolizumab 400 mg subcutaneously at weeks 0, 2, and 4. At six weeks, 64 percent had achieved a response and 39 percent had achieved remission. Maintenance treatment with certolizumab pegol 400 mg every two weeks was not superior to 400 mg every four weeks over one year of treatment. In a separate analysis, the authors also found that treatment with certolizumab at either maintenance dose was associated with improvements in health-related quality of life, daily activity, and work productivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H159259361\">",
"    <span class=\"h2\">",
"     Certolizumab for patients with fistulizing disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small randomized controlled trial of a subgroup from the PRECiSE 2 trial found that 36 percent of patients had complete fistula closure, almost entirely perianal, compared with 17 percent receiving placebo (p = 0.038) at week 26 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of adverse events have been described following treatment with anti-TNF-alpha agents. These are summarized separately along with recommendations for screening patients prior to starting these medications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One series of patients with drug-induced lupus erythematosus (DILE) suggested that this complication may not be a class effect occurring in all anti-TNF agents. Some patients who experienced DILE while being treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    did not develop this reaction with certolizumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADALIMUMAB VERSUS INFLIXIMAB VERSUS CERTOLIZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and certolizumab have generally shown similar results but no studies have directly compared them. The decision to use adalimumab, infliximab, or certolizumab in patients with Crohn's disease requiring anti-TNF therapy will mostly be influenced by the convenience (and availability in individual countries) of subcutaneous administration of adalimumab and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    contrasted against the larger body of safety and efficacy data on intravenous infliximab. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6329?source=see_link&amp;anchor=H11188279#H11188279\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Anti-TNF therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1147346604\">",
"    <span class=\"h2\">",
"     Certolizumab for patients having failed one or two previous anti-TNF agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients appear to respond best to their initial anti-TNF agent but certolizumab as a second- or third-line anti-TNF agent still may produce a significant benefit. An analysis of the PRECiSE 2 data suggested that individuals with prior treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    responded at week 26 at a higher rate than patients receiving placebo (response: 44 versus 25 percent; remission: 33 versus 14 percent) but not as robustly as infliximab-na&iuml;ve patients (response: 69 versus 40 percent; remission: 53 versus 33 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/15\">",
"     15",
"    </a>",
"    ]. A large open-labeled series suggested a high rate of response in patients who responded to infliximab but then either lost response or became intolerant to it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/11\">",
"     11",
"    </a>",
"    ]. Certolizumab as a third-line anti-TNF agent in patients who responded to infliximab and or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    or became intolerant to those agents was reported to have a response rate of 61 percent at six weeks, with 45 percent of patients still under treatment at the end of nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33829/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"       Certolizumab pegol",
"      </a>",
"      (Cimzia&reg;) is a humanized monoclonal antibody Fab fragment linked to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/17/4374?source=see_link\">",
"       polyethylene glycol",
"      </a>",
"      . Possible advantages compared with other TNF agents are its longer half-life (and need for less frequent dosing) and potential for less immunogenicity, although the latter has not been demonstrated.",
"     </li>",
"     <li>",
"      Indications are similar to those for other TNF agents. Whether it offers a clinical advantage to other TNF agents or other approaches to management of patients with moderate to severe Crohn's disease has not been evaluated directly. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      be used in patients with moderate to severe Crohn's disease who had an inadequate response to conventional therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ), although other approaches may be equally effective. There are no clinical trials that have compared certolizumab pegol to other anti-TNF therapies. Issues related to the choice among anti-TNF therapies for Crohn's disease are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6329?source=see_link&amp;anchor=H11188279#H11188279\">",
"       \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Anti-TNF therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preliminary data suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      can also be effective in patients who responded to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      and lost response or became intolerant to it. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Patients previously treated with infliximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who respond, we suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"       certolizumab pegol",
"      </a>",
"      be used for maintenance therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, efficacy and safety for long-term maintenance have not been established.",
"     </li>",
"     <li>",
"      The recommended dosing for induction is 400 mg subcutaneously at weeks 0, 2 and 4 and then every four weeks for maintenance of response.",
"     </li>",
"     <li>",
"      A number of adverse events have been described following treatment with anti-TNF-alpha agents. These are summarized separately along with recommendations for screening patients prior to starting these medications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/1\">",
"      Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007; 13:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/2\">",
"      Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/3\">",
"      Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/4\">",
"      Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/5\">",
"      Shao LM, Chen MY, Cai JT. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease. Aliment Pharmacol Ther 2009; 29:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/6\">",
"      Lichtenstein GR, Thomsen O&Oslash;, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010; 8:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/7\">",
"      Sandborn WJ, Schreiber S, Hanauer SB, et al. Reinduction with certolizumab pegol in patients with relapsed Crohn's disease: results from the PRECiSE 4 Study. Clin Gastroenterol Hepatol 2010; 8:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/8\">",
"      Rutgeerts P, Schreiber S, Feagan B, et al. Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFalpha, improves health-related quality of life in patients with moderate to severe Crohn's disease. Int J Colorectal Dis 2008; 23:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/9\">",
"      Feagan BG, Coteur G, Tan S, et al. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am J Gastroenterol 2009; 104:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/10\">",
"      Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/11\">",
"      Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010; 8:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/12\">",
"      Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011; 33:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/13\">",
"      Schreiber S, Lawrance IC, Thomsen O&Oslash;, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther 2011; 33:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/14\">",
"      Subramanian S, Yajnik V, Sands BE, et al. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis 2011; 17:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/15\">",
"      Hanauer SB, Panes J, Colombel JF, et al. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 32:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33829/abstract/16\">",
"      Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010; 31:92.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4053 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-160F99BB66-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33829=[""].join("\n");
var outline_f33_2_33829=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Patients previously treated with infliximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H159259361\">",
"      Certolizumab for patients with fistulizing disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADALIMUMAB VERSUS INFLIXIMAB VERSUS CERTOLIZUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1147346604\">",
"      Certolizumab for patients having failed one or two previous anti-TNF agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_2_33830="Warfarin: Patient drug information";
var content_f33_2_33830=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Warfarin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     see \"Warfarin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/4/21578?source=see_link\">",
"     see \"Warfarin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coumadin&reg;;",
"     </li>",
"     <li>",
"      Jantoven&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F234877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Warfarin&reg;;",
"     </li>",
"     <li>",
"      Coumadin&reg;;",
"     </li>",
"     <li>",
"      Mylan-Warfarin;",
"     </li>",
"     <li>",
"      Novo-Warfarin;",
"     </li>",
"     <li>",
"      Taro-Warfarin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3821684",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause very bad bleeding. Follow how to use exactly. Have your blood work checked as you have been told by your doctor, do not miss visits. Closely read the part in this leaflet which lists when to call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin the blood so that clots will not form.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703136",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to warfarin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705273",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Anesthesia given in your spine, aneurysm, bleeding problems, diverticulitis, drink too much alcohol, heart valve infection, liver disease, low platelet count, pericarditis, polyarthritis, poor eating habits, recent surgery of the eye or brain, very high blood pressure, unsteadiness, or warfarin-induced necrosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you know that you will not take the drug as you have been told.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697120",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you fall a lot, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696746",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not donate blood while using this drug and for 5 days after stopping.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before taking multivitamins, natural products, and diet aids. These may have vitamin K in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697357",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you stop smoking, talk with your doctor. How much drug you take may need to be changed.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fall or crash when you hit your head. Talk with your doctor even if you feel fine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Coughing up blood.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699115",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throwing up blood or throw up that looks like coffee grounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699034",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very heavy periods (menstrual bleeding).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698617",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in skin color to black or purple.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698601",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       An infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705472",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral and shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695270",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep your use of vitamin K the same from day to day. Talk with your doctor. Do not make changes in your normal diet. Eat only little bits of green, leafy veggies (alfalfa, asparagus, broccoli, brussel sprouts, collard greens, cabbage, cauliflower, kale, lettuce, spinach, water cress), green tea, liver, and some veggie oils. Foods like these may change how this drug works.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695245",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11147 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33830=[""].join("\n");
var outline_f33_2_33830=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234876\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234877\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028947\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028949\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028948\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028953\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028954\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028956\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028951\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028952\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028957\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028958\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=related_link\">",
"      Warfarin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/4/21578?source=related_link\">",
"      Warfarin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_2_33831="Minor pelvic fractures in the elderly";
var content_f33_2_33831=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Minor pelvic fractures in the elderly",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33831/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33831/contributors\">",
"     James Fiechtl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33831/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33831/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33831/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33831/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33831/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/2/33831/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2202596\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor pelvic fractures in the elderly involve either low energy mechanisms or repetitive stresses in osteoporotic bone (insufficiency fractures). These fractures may be either displaced or non-displaced and generally involve both anterior and posterior elements of the pelvis. For the purposes of this review, low energy and pelvic insufficiency fractures will be considered together as some degree of insufficiency is universally present.",
"   </p>",
"   <p>",
"    The diagnosis and management of minor low-energy and insufficiency pelvic fractures in elder patients is reviewed here. Such fractures consist primarily of fractures of the pubic rami and the sacral ala. Osteoporosis, hip fractures, and major pelvic trauma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/31/18937?source=see_link\">",
"     \"Hip fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22650?source=see_link\">",
"     \"Pelvic trauma: Initial evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/16/25865?source=see_link\">",
"     \"Severe pelvic fracture in the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202603\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202611\">",
"    <span class=\"h2\">",
"     Incidence and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic fractures represent approximately 3 percent of all skeletal injuries, regardless of age; however, data about minor pelvic fractures specifically in elder patients are limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/1\">",
"     1",
"    </a>",
"    ]. A Finnish population study determined the incidence for pelvic insufficiency fractures to be 92 per 100,000. This number represents approximately one-fifth the incidence of femoral neck fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence of these fractures is increasing: from 1988 to 2000, the incidence increased 58.4 percent in men and 110.8 percent in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review of 181 elder patients with pelvic insufficiency fractures reported an associated mortality rate of 23 percent at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/4\">",
"     4",
"    </a>",
"    ]. This rate did not vary significantly with fracture location or the degree of fracture displacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10341689\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for these injuries are similar to those for osteoporosis: advanced age, prior pelvic fracture, glucocorticoid therapy, low body weight, smoking, and excess alcohol intake. Additional risk factors include a history of pelvic radiation, Pagets disease, rheumatoid arthritis, and multiple myeloma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H17#H17\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical risk factor assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202618\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pelvic insufficiency fractures most commonly involve the pubic rami and, unlike major pelvic trauma, can occur in isolation. Sacral insufficiency fractures most commonly involve the sacral ala (zone 1), either unilateral or bilateral (",
"    <a class=\"graphic graphic_figure graphicRef76695 \" href=\"mobipreview.htm?26/17/26900\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57811 \" href=\"mobipreview.htm?5/56/6026\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/6\">",
"     6",
"    </a>",
"    ]. These injuries rarely occur in isolation; 88 percent of patients have coexisting insufficiency fractures of the pubic rami, parasymphyseal,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    iliac crest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/7\">",
"     7",
"    </a>",
"    ]. Pelvic anatomy is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22650?source=see_link&amp;anchor=H6#H6\">",
"     \"Pelvic trauma: Initial evaluation and management\", section on 'Anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202625\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202633\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of elder patients with minor pelvic fractures present atraumatically, with only one-third presenting after minor trauma (eg, fall from standing) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients may have persistent symptoms for weeks or months, as the diagnosis is often missed initially or delayed. Patients may complain of lower back pain or groin pain, and are often misdiagnosed as having degenerative disc disease, spinal stenosis, or lumbar spondylosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients may describe increasing difficulty with ambulation, limiting their activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202648\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial inspection should focus on the position of the lower extremities and leg length differences. Next, palpate the major bony landmarks, including the sacrum, sacroiliac joints, iliac crests, pubic rami, and pubic symphysis. The presence of a leg length discrepancy, abnormal positioning of the leg, focal bony tenderness around the pelvis or hip, or reluctance of the patient to move their leg all raises suspicion for a pelvic injury. A careful examination of the groin should be performed to assess for other potential causes of hip pain (eg, inguinal hernia).",
"   </p>",
"   <p>",
"    Following palpation, ask the patient to perform a straight-leg raise. If the patient is unable to raise their leg, defer range of motion and strength testing until imaging is obtained.",
"   </p>",
"   <p>",
"    A screening neurovascular examination should be performed, although the minor pelvic fractures discussed here are unlikely to present with neurovascular deficits. Approximately 5 percent of such injuries present with neurologic symptoms, most commonly sacral radiculopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/10\">",
"     10",
"    </a>",
"    ]. Palpate the distal pulses and assess basic motor and sensory function of both lower extremities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=see_link\">",
"     \"The detailed neurologic examination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202655\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC IMAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6816696\">",
"    <span class=\"h2\">",
"     Approach to imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally obtain a plain radiograph of the pelvis for elder patients at risk for minor pelvic fracture. Plain radiographs can reveal many types of hip, pelvic, and lumbosacral spine fractures and are a useful tool for working through the differential diagnosis of hip, groin, and low back pain in elder patients.",
"   </p>",
"   <p>",
"    If plain x-rays of the pelvis are negative but clinical suspicion is high, we obtain an MRI. If the x-rays are negative and clinical suspicion is low (eg, patient is able to ambulate and strength is at baseline), the patient may follow-up in the out-patient setting. At follow-up, plain radiographs should be repeated if the patient experiences persistent or worsening symptoms. If these x-rays are indeterminate or clinical suspicion is moderate or high, we obtain an MRI.",
"   </p>",
"   <p>",
"    In resource-limited settings, it is reasonable to treat patient empirically without advanced imaging studies if the initial x-ray is negative but symptoms persist, assuming important alternative diagnoses have been sufficiently ruled out and appropriate follow-up can be ensured.",
"   </p>",
"   <p>",
"    In general, distinguishing between minor and major pelvic fracture is less important than determining the presence or absence of a fracture. Any fracture type or location seen on plain radiographs of the pelvis may be associated with significant bleeding or additional injuries. However, the insufficiency fractures discussed in this topic, which may be missed on plain radiographs, are unlikely to be associated with such complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202663\">",
"    <span class=\"h2\">",
"     Plain radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs are the initial study of choice for elder patients with suspected minor pelvic fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83499 \" href=\"mobipreview.htm?42/0/43008\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85969 \" href=\"mobipreview.htm?33/60/34757\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85973 \" href=\"mobipreview.htm?30/9/30868\">",
"     image 3",
"    </a>",
"    ). However, the sensitivity of plain x-rays for pelvic insufficiency fractures is limited. Studies report miss rates ranging from 4.4 to 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Specialized radiographs (inlet and outlet views) can be obtained, but whether these studies improve sensitivity for insufficiency fractures is not known.",
"   </p>",
"   <p>",
"    Inlet views with the x-ray beam projected 40 degrees cephalad better defines the pelvic brim (",
"    <a class=\"graphic graphic_figure graphicRef65489 \" href=\"mobipreview.htm?34/26/35232\">",
"     figure 3",
"    </a>",
"    ); outlet views with the x-ray beam projected 40 degrees caudal provide better images of the sacrum and sacroiliac joint (",
"    <a class=\"graphic graphic_figure graphicRef68451 \" href=\"mobipreview.htm?39/25/40336\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202670\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;If plain radiographs are indeterminate, computed tomography (CT) scans are sometimes obtained (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85971 \" href=\"mobipreview.htm?34/54/35682\">",
"     image 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85974 \" href=\"mobipreview.htm?35/47/36593\">",
"     image 5",
"    </a>",
"    ). However, the sensitivity of CT for minor pelvic fractures is also limited. One study comparing CT and MRI reported that CT had a sensitivity for occult pelvic fractures of 77 percent and for occult sacral fractures of 66 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202677\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) remains the gold standard for evaluating minor pelvic fractures in elder patients. Reported sensitivities for MRI are 96.3 percent for occult pelvic fractures and 98.6 percent for occult sacral fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/14\">",
"     14",
"    </a>",
"    ]. MRI should be obtained when plain radiographs are negative but clinical suspicion for pelvic fracture remains high (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83835 \" href=\"mobipreview.htm?13/2/13349\">",
"     image 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85972 \" href=\"mobipreview.htm?20/59/21433\">",
"     image 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef85968 \" href=\"mobipreview.htm?24/60/25543\">",
"     image 8",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10341825\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor low-energy and insufficiency pelvic fractures occur primarily in the pubic rami and the sacral ala. The diagnosis of these minor pelvic fractures in elder patients is made radiographically using plain x-rays and possibly magnetic resonance imaging (MRI), if suspicion persists in the face of negative x-rays. However, diagnosis is often delayed and appropriate imaging is often only obtained when clinicians carefully consider the presentation and examination findings. Pelvic fracture should be considered in any elder patient complaining of hip, groin, or low back pain, particularly those with risk factors for fracture (eg, osteoporosis, low body weight, glucocorticoid therapy) and persistent symptoms. A negative MRI rules out the diagnosis in the great majority of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10341832\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for sacral and rami insufficiency fractures is broad and determined primarily by the site of pain. The most common conditions in the differential for sacral pain are, not surprisingly, those commonly misdiagnosed for sacral insufficiency fractures. They include lumbar spine pathology such as spondylosis, discitis, disc herniation, and vertebral compression fractures. Unfortunately, these conditions have many overlapping symptoms and signs. Disc herniations and discitis are more likely to present with radicular symptoms than sacral insufficiency fractures. However, these conditions and others included in the differential, such as spondylosis, minimal vertebral compression fractures, and sacroiliitis, generally require advanced imaging studies to differentiate them from insufficiency fractures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12520?source=see_link\">",
"     \"Evaluation of thoracic and lumbar spinal column injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=see_link\">",
"     \"Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis for insufficiency fractures of the pubic rami includes conditions that present primarily with groin pain, such as inguinal hernia, lymphadenopathy, retroperitoneal hemorrhage, and genitourinary processes (eg, urinary retention, urinary tract infection, nephrolithiasis). Genitourinary (GU) cancers, including those affecting the bladder, prostate, uterus, and ovaries, may all present with groin pain. Inguinal hernias and lymphadenopathy can usually be identified by physical examination. Most GU conditions can be identified with a careful history and focused diagnostic studies, such as urinalysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31321?source=see_link\">",
"     \"Classification, clinical features and diagnosis of inguinal and femoral hernias in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35912?source=see_link\">",
"     \"Acute urinary retention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=see_link\">",
"     \"Diagnosis and acute management of suspected nephrolithiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=see_link\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/6/37992?source=see_link\">",
"     \"Endometrial carcinoma: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vascular disorders may present with symptoms suggesting pelvic insufficiency fractures. Arterial insufficiency can present with posterior pelvic pain and should be assessed with a neurovascular examination. Aneurysms, depending upon their location (eg, iliac artery), can present with groin pain, as may venous thromboembolic disease with proximal or deep pelvic vein involvement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29304?source=see_link\">",
"     \"Iliac artery aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Particularly in elder patients, clinicians must beware of intraabdominal conditions presenting with groin pain or in other &ldquo;atypical&rdquo; ways. Abdominal pain in older adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link&amp;anchor=H33#H33\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Older adults'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link\">",
"     \"Diagnostic approach to abdominal pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41770?source=see_link\">",
"     \"Evaluation of the adult with abdominal pain in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the insufficiency fractures discussed in this topic, plain radiographs of the pelvis and hip may reveal hip fractures or more severe pelvic fractures, but this is unlikely without a history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    examination findings associated with trauma. Plain radiographs of the lumbar spine may reveal compression fractures, degenerative disc disease, or spondylosis. Otherwise, plain radiographs of the abdomen and pelvis have limited utility, but may show a ureteral calcification, abdominal obstruction, or vascular calcifications. Hip and major pelvic fractures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/31/18937?source=see_link\">",
"     \"Hip fractures in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22650?source=see_link\">",
"     \"Pelvic trauma: Initial evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/16/25865?source=see_link\">",
"     \"Severe pelvic fracture in the adult trauma patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12520?source=see_link\">",
"     \"Evaluation of thoracic and lumbar spinal column injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/20/20810?source=see_link\">",
"     \"Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202691\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202699\">",
"    <span class=\"h2\">",
"     Initial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial management goals for elder patients with minor pelvic fractures are pain control and early mobilization. Opioids are often required initially for patients with severe fracture pain. However, many elder patients are more susceptible to the potentially dangerous side effects of opioids (eg, respiratory depression), and therefore it is best to start with smaller doses than are used for younger adults and titrate as needed. The frequency of dosing is generally left unchanged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/58/17318?source=see_link&amp;anchor=H7#H7\">",
"     \"General principles of acute fracture management\", section on 'Pain management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early mobilization is a key component to reducing complications from pelvic fractures. A minority of sacral insufficiency fractures require that patients be non-weightbearing, but in most cases (eg, sacral ala fractures) patients are permitted to bear weight as tolerated. All other pelvic insufficiency fractures occur in locations that allow for weightbearing. Physical therapy is often useful for gait training, including the use of aids such as crutches or a walker. Activity can be advanced as the patient tolerates.",
"   </p>",
"   <p>",
"    As long as the patient is mobile, prophylactic medical therapy for deep vein thrombosis is not required. Otherwise, standard prophylaxis should be given. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in medical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202713\">",
"    <span class=\"h1\">",
"     DEFINITIVE MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202721\">",
"    <span class=\"h2\">",
"     Specialty consultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive treatment for insufficiency fractures of the pelvis (eg, sacroplasty and ramoplasty) has been described but is not well studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33831/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. Indications remain unspecified, but consultation is reasonable when pain control is difficult and mobilization remains limited. These procedures are performed primarily by interventional radiologists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202736\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of elder patients with pelvic fractures require hospital admission for pain control and physical therapy. However, if the patient can ambulate and pain is adequately controlled, they may be discharged to a rehabilitation facility or home, provided they have a good support system at home and close medical follow-up is arranged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202743\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;No definitive guidelines exist for follow-up. The author prefers to have patients follow-up within one week for repeat radiographs to ensure no gross fracture displacement has occurred. The one-week follow-up appointment also provides an opportunity to assess mobility and pain control. Thereafter, the patient is seen every three weeks until clinically healed (ie, pain free with ambulation returned to baseline). Clinical healing generally occurs within six to eight weeks, and we usually obtain repeat radiographs at that time to assess healing (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83967 \" href=\"mobipreview.htm?16/42/17056\">",
"     image 9",
"    </a>",
"    ). Plain radiographs are also obtained if there is any change in the patient&rsquo;s symptoms, such as increased pain or new weakness.",
"   </p>",
"   <p>",
"    During follow-up, appropriate assessment of bone density and osteoporosis should be performed for patients with insufficiency fractures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202750\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective review of 181 elder patients with pelvic insufficiency fractures reported an associated mortality rate of 23 percent at one year. In addition, this series reported an increase in the number of patients requiring ambulatory aids and a greater need for higher levels of care (eg, more patients leaving their home for either assisted living or a nursing home). These developments occurred regardless of fracture type.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2202757\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minor pelvic fractures in the elderly involve either low energy mechanisms or repetitive stresses in osteoporotic bone (insufficiency fractures). Pelvic insufficiency fractures most commonly involve the pubic rami and can occur in isolation. Sacral insufficiency fractures most commonly involve the sacral ala, either unilateral or bilateral, and usually coexist with insufficiency fractures of the pubic rami, parasymphysis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      iliac crest. (See",
"      <a class=\"local\" href=\"#H2202603\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for these injuries are similar to those for osteoporosis: advanced age, prior pelvic fracture, glucocorticoid therapy, low body weight, smoking, and excess alcohol intake.",
"     </li>",
"     <li>",
"      Sacral and pelvic insufficiency fractures are often missed. Suspect the fracture in elder patients with new or persistent pain or focal bony tenderness in the pelvis, hip, or groin region, a leg length discrepancy, or reluctance to move either of their lower extremities.",
"     </li>",
"     <li>",
"      Most elder patients with minor pelvic fractures present atraumatically; only one-third present after minor trauma (eg, fall from standing). Patients may have symptoms for weeks or months, and may complain of lower back pain or groin pain. (See",
"      <a class=\"local\" href=\"#H2202633\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of a leg length discrepancy, abnormal positioning of the leg, focal bony tenderness around the pelvis or hip, or reluctance of the patient to move their leg all raises suspicion for a pelvic injury. (See",
"      <a class=\"local\" href=\"#H2202648\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of minor pelvic fractures in elder patients is made radiographically. We generally obtain a plain radiograph of the pelvis for elder patients at risk for minor pelvic fracture. However, the sensitivity of plain x-rays is limited. If the x-rays are negative but clinical suspicion is high, we obtain an MRI. (See",
"      <a class=\"local\" href=\"#H2202655\">",
"       'Diagnostic imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate pain control and early mobilization are central to preventing complications and successfully managing these fractures in elder patients. Physical therapy is often helpful for gait training. Consultation and follow-up care are reviewed in the text. (See",
"      <a class=\"local\" href=\"#H2202691\">",
"       'Management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2202713\">",
"       'Definitive management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5753384\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/1\">",
"      Grotz MR, Allami MK, Harwood P, et al. Open pelvic fractures: epidemiology, current concepts of management and outcome. Injury 2005; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/2\">",
"      Kannus P, Palvanen M, Niemi S, et al. Epidemiology of osteoporotic pelvic fractures in elderly people in Finland: sharp increase in 1970-1997 and alarming projections for the new millennium. Osteoporos Int 2000; 11:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/3\">",
"      Boufous S, Finch C, Lord S, Close J. The increasing burden of pelvic fractures in older people, New South Wales, Australia. Injury 2005; 36:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/4\">",
"      Mears SC, Berry DJ. Outcomes of displaced and nondisplaced pelvic and sacral fractures in elderly adults. J Am Geriatr Soc 2011; 59:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/5\">",
"      Lyders EM, Whitlow CT, Baker MD, Morris PP. Imaging and treatment of sacral insufficiency fractures. AJNR Am J Neuroradiol 2010; 31:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/6\">",
"      Denis F, Davis S, Comfort T. Sacral fractures: an important problem. Retrospective analysis of 236 cases. Clin Orthop Relat Res 1988; 227:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/7\">",
"      De Smet AA, Neff JR. Pubic and sacral insufficiency fractures: clinical course and radiologic findings. AJR Am J Roentgenol 1985; 145:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/8\">",
"      Finiels H, Finiels PJ, Jacquot JM, Strubel D. [Fractures of the sacrum caused by bone insufficiency. Meta-analysis of 508 cases]. Presse Med 1997; 26:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/9\">",
"      Schindler OS, Watura R, Cobby M. Sacral insufficiency fractures. J Orthop Surg (Hong Kong) 2007; 15:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/10\">",
"      Gotis-Graham I, McGuigan L, Diamond T, et al. Sacral insufficiency fractures in the elderly. J Bone Joint Surg Br 1994; 76:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/11\">",
"      Bogost GA, Lizerbram EK, Crues JV 3rd. MR imaging in evaluation of suspected hip fracture: frequency of unsuspected bone and soft-tissue injury. Radiology 1995; 197:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/12\">",
"      Kirby MW, Spritzer C. Radiographic detection of hip and pelvic fractures in the emergency department. AJR Am J Roentgenol 2010; 194:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/13\">",
"      Dominguez S, Liu P, Roberts C, et al. Prevalence of traumatic hip and pelvic fractures in patients with suspected hip fracture and negative initial standard radiographs--a study of emergency department patients. Acad Emerg Med 2005; 12:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/14\">",
"      Henes FO, N&uuml;chtern JV, Groth M, et al. Comparison of diagnostic accuracy of Magnetic Resonance Imaging and Multidetector Computed Tomography in the detection of pelvic fractures. Eur J Radiol 2012; 81:2337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/15\">",
"      Gupta DK, Avram MJ. Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy. Clin Pharmacol Ther 2012; 91:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33831/abstract/16\">",
"      Beall DP, Datir A, D'Souza SL, et al. Percutaneous treatment of insufficiency fractures : principles, technique and review of literature. Skeletal Radiol 2010; 39:117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83171 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33831=[""].join("\n");
var outline_f33_2_33831=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2202757\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202596\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202603\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2202611\">",
"      Incidence and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10341689\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202618\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202625\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2202633\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2202648\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202655\">",
"      DIAGNOSTIC IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6816696\">",
"      Approach to imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2202663\">",
"      Plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2202670\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2202677\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10341825\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10341832\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202691\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2202699\">",
"      Initial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202713\">",
"      DEFINITIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2202721\">",
"      Specialty consultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2202736\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2202743\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202750\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2202757\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5753384\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/83171\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83171|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/0/43008\" title=\"diagnostic image 1\">",
"      AP Pelvic x-ray with osteopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/60/34757\" title=\"diagnostic image 2\">",
"      X-ray insufficiency fracture of the pubic ramus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?30/9/30868\" title=\"diagnostic image 3\">",
"      X-ray insufficiency fracture of the sacrum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?34/54/35682\" title=\"diagnostic image 4\">",
"      CT scan insufficiency fracture of the pubic ramus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/47/36593\" title=\"diagnostic image 5\">",
"      CT scan insufficiency fracture of the sacrum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/2/13349\" title=\"diagnostic image 6\">",
"      MRI sacral ala insufficiency fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?20/59/21433\" title=\"diagnostic image 7\">",
"      MRI insufficiency fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?24/60/25543\" title=\"diagnostic image 8\">",
"      MRI pubic ramus insufficiency fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?16/42/17056\" title=\"diagnostic image 9\">",
"      Healing pubic ramus fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/83171|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/17/26900\" title=\"figure 1\">",
"      Anterior and posterior columns of acetabulum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/56/6026\" title=\"figure 2\">",
"      Bones and ligaments of the pelvis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/26/35232\" title=\"figure 3\">",
"      Pelvic inlet view xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/25/40336\" title=\"figure 4\">",
"      Pelvic outlet view xray",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/4/35912?source=related_link\">",
"      Acute urinary retention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/37/31321?source=related_link\">",
"      Classification, clinical features and diagnosis of inguinal and femoral hernias in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=related_link\">",
"      Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/50/20266?source=related_link\">",
"      Diagnosis and acute management of suspected nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/6/37992?source=related_link\">",
"      Endometrial carcinoma: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/50/41770?source=related_link\">",
"      Evaluation of the adult with abdominal pain in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/14/12520?source=related_link\">",
"      Evaluation of thoracic and lumbar spinal column injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/58/17318?source=related_link\">",
"      General principles of acute fracture management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/31/18937?source=related_link\">",
"      Hip fractures in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/39/29304?source=related_link\">",
"      Iliac artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/20/20810?source=related_link\">",
"      Lumbosacral radiculopathy: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/7/22650?source=related_link\">",
"      Pelvic trauma: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/16/25865?source=related_link\">",
"      Severe pelvic fracture in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_2_33832="Pressures variable obstr HCM";
var content_f33_2_33832=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 478px\">",
"   <div class=\"ttl\">",
"    Pressure tracing in variably obstructive hypertrophic cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 458px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top tracing shows simultaneously recorded left ventricular (LV) and aortic (Ao) pressures. The systolic LV and Ao pressures are equivalent and no gradient is present, even after a ventricular premature beat (VPB). Valsalva induces more frequent VPBs and an intraventricular gradient is provoked; the beat following the VPB results in a LV pressure that is significantly greater than the Ao pressure (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton Kern, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33832=[""].join("\n");
var outline_f33_2_33832=null;
var title_f33_2_33833="Neuroacanthocytosis";
var content_f33_2_33833=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neuroacanthocytosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33833/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33833/contributors\">",
"     Jeffrey Ralph, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33833/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33833/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33833/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33833/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/2/33833/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1982873\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroacanthocytosis refers to a group of rare diseases that share the features of central nervous system degeneration, neuromuscular manifestations, and acanthocytosis on a peripheral blood smear.",
"   </p>",
"   <p>",
"    An acanthocyte is a spiculated form of a red blood cell (",
"    <a class=\"graphic graphic_picture graphicRef80080 \" href=\"mobipreview.htm?14/26/14760\">",
"     picture 1",
"    </a>",
"    ). The name is derived from the Greek word (acantha) for thorn. It should be differentiated from the echinocyte, which has more numerous, uniform, and finer spiny projections and is associated with severe renal and liver disease.",
"   </p>",
"   <p>",
"    Acanthocytes may be seen in a variety of diseases, including severe liver disease. In neuroacanthocytosis, the degree of neurologic impairment does not correlate with the degree of acanthocytosis on the smear. &nbsp;",
"   </p>",
"   <p>",
"    The general category of neuroacanthocytosis includes abetalipoproteinemia, chorea-acanthocytosis, and McLeod syndrome. Acanthocytes appear more variably in pantothenate kinase-associated neurodegeneration and in Huntington disease-like 2. These disorders are discussed here. Acanthocytosis in liver and other systemic disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9305?source=see_link&amp;anchor=H2#H2\">",
"     \"Spiculated cells (echinocytes and acanthocytes) and target cells\", section on 'Echinocytes and acanthocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1983214\">",
"    <span class=\"h1\">",
"     ABETALIPOPROTEINEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abetalipoproteinemia, also known as Bassen-Kornzweig disease, is an autosomal recessive disorder caused by mutations encoding the microsomal triglyceride transfer protein (MTP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This protein is essential for the formation and eventual secretion of apolipoprotein B-containing lipoproteins, both from the intestine (chylomicrons) and liver (LDL and VLDL). Chylomicron formation is necessary for absorption and initial transport of the fat-soluble vitamins.",
"   </p>",
"   <p>",
"    The neurologic manifestations of abetalipoproteinemia result from the inability to absorb and transport vitamin E [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/5\">",
"     5",
"    </a>",
"    ]. Vitamin A deficiency may also contribute to the retinal degeneration. Neuropathologic changes affect posterior columns and spinocerebellar tracts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1982880\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder typically presents in early childhood with steatorrhea, abdominal distension, and failure to thrive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/4,6,7\">",
"     4,6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of the causes of chronic diarrhea in children\", section on 'Steatorrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clumsiness may be the first neurologic manifestation. During childhood or adolescence, progressive ataxia, neuropathy, and vision impairment develop. Impaired visual acuity and visual field defects are common. Funduscopic examination reveals pigmentary degeneration of the retina (retinitis pigmentosa). Dysarthria is common. The sensory motor neuropathy manifests with weakness and distal muscle atrophy. Reflexes are diminished or absent, although extensor plantar responses may be present. There is truncal and limb ataxia. Proprioceptive sensory loss and possibly impaired pain and temperature sensation occur as well.",
"   </p>",
"   <p>",
"    The clinical presentation is virtually indistinguishable from that associated with severe vitamin E deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of vitamin E\", section on 'Deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88328206\">",
"    <span class=\"h2\">",
"     Laboratory and test findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic laboratory findings include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Triglyceride levels and total cholesterol levels are very low (less than 1.5",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Lipoprotein electrophoresis will reveal the absence of beta-lipoproteins. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H180677128#H180677128\">",
"       \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Abetalipoproteinemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acanthocytes constitute 50 to 90 percent of the circulating red blood cell population. A mild, normocytic anemia is common.",
"     </li>",
"     <li>",
"      Sensory nerve conduction studies have shown absent nerve action potentials (SNAPs) or SNAPs of reduced amplitudes. Conduction velocities are usually normal (despite features of peripheral nerve demyelination on pathology specimens) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Motor nerve conduction studies may be normal.",
"     </li>",
"     <li>",
"      Vitamin E levels (alpha-tocopherol and gamma-tocopherol) are undetectable or very low.",
"     </li>",
"     <li>",
"      Some patients develop elevated transaminases due to hepatic steatosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Homozygotes may have an impaired cortisol response to ACTH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88328191\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of abetalipoproteinemia is based on the clinical findings and the striking abnormalities on serum lipid analysis. Molecular genetic testing for mutations of the MTP gene is not currently commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1982894\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic findings in abetalipoproteinemia are similar to those found in a number of the dominantly-inherited spinocerebellar atrophy syndromes, including Machado Joseph disease and Friedreich ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=see_link\">",
"     \"The spinocerebellar ataxias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15432?source=see_link\">",
"     \"Friedreich ataxia\"",
"    </a>",
"    .) The autosomal recessive inheritance, presence of acanthocytes, and abnormal lipid studies of abetalipoproteinemia are important distinguishing features.",
"   </p>",
"   <p>",
"    Abetalipoproteinemia is distinguished from severe vitamin E deficiency by the absence of apolipoprotein B-containing lipoproteins. The lipid profile also helps distinguish it from a rare autosomal recessive ataxia (ataxia with vitamin E deficiency, AVED) associated with low or absent vitamin E levels and normal lipids; this entity is associated with mutations of the alpha-tocopherol transfer protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Vitamin E supplementation slows progression and may improve ataxia in these conditions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of vitamin E\", section on 'Deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations in the apolipoprotein B gene cause hypobetalipoproteinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/4,15-18\">",
"     4,15-18",
"    </a>",
"    ]. Individuals homozygous for these mutations may present with clinical findings indistinguishable from abetalipoproteinemia. Heterozygotes typically have milder phenotypes and low but detectable VLDL and LDL levels. As in abetalipoproteinemia, triglyceride and cholesterol levels are very low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H180677135#H180677135\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Hypobetalipoproteinemia'",
"    </a>",
"    .) Diagnosis is based on the autosomal codominant pattern of inheritance, clinical features, and",
"    <span class=\"nowrap\">",
"     lipid/lipoprotein",
"    </span>",
"    analysis. Commercial molecular genetic testing for mutations in the apolipoprotein B gene is not currently available. Patients are treated with vitamin E supplementation.",
"   </p>",
"   <p>",
"    A similar disorder characterized by hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (called the HARP syndrome) is caused by mutations of the PANK2 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. (See",
"    <a class=\"local\" href=\"#H4519453\">",
"     'Pantothenate kinase-associated neurodegeneration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1982943\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurologic manifestations of abetalipoproteinemia can be prevented and at least partially reversed with the administration of vitamin E, 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/7,22-26\">",
"     7,22-26",
"    </a>",
"    ]. Analysis of vitamin E levels in adipose tissue biopsies can be used to assess adequacy of vitamin E dosing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The other fat-soluble vitamins (A, K, and D) should also be supplemented, but precise dosing recommendations have not been established. Vitamin A 100 to 400",
"    <span class=\"nowrap\">",
"     IU/kg/day",
"    </span>",
"    has been a suggested dose; serum carotene concentrations can help guide titration and avoid toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A longitudinal study of patients with abetalipoproteinemia and hypobetalipoproteinemia showed that mild retinal degeneration may occur despite supplementation with both vitamins E and A [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dietary modification to limit fat intake ameliorates the gastrointestinal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1982957\">",
"    <span class=\"h1\">",
"     CHOREA-ACANTHOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorea-acanthocytosis has also been called choreoacanthocytosis, familial amyotrophic chorea with acanthocytosis, familial amyotrophic choreoacanthocytosis, and Levine-Critchley syndrome.",
"   </p>",
"   <p>",
"    This is an autosomal recessive disorder caused by mutations in the VPS13A (previously called CHAC) gene, which encodes a large protein called chorein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. The function of chorein is not known. This protein is expressed in many body tissues, including erythrocyte membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disorder is very rare, with an estimated 1000 cases worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"     33",
"    </a>",
"    ]. Clusters of disease have been described in Japan and in French-Canada.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1982964\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, this disorder is characterized by the onset in young adulthood of chorea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parkinsonism, oro-lingual-facial dystonias, tics, social disinhibition, seizures, areflexia, and distal muscle wasting.",
"   </p>",
"   <p>",
"    The mean age of onset is 35 years with a broad range from the first to the seventh decade. Initial clinical symptoms can vary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The movement disorder is often the most prominent clinical feature. Chorea is the typical manifestation, although some patients may present with parkinsonism (bradykinesia and rigidity) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/34,35\">",
"       34,35",
"      </a>",
"      ]. Flinging arm and leg movements, shoulder shrugs, and pelvic thrusts are common [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/36\">",
"       36",
"      </a>",
"      ]. Ambulation is usually severely affected with an odd lurching type of gait. Postural reflexes are impaired and falls are very common. Violent trunk spasms with head banging may occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/37\">",
"       37",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Dystonias affecting the mouth region and pharynx are characteristic. Repetitive tongue protrusions, so-called &ldquo;feeding dystonia&rdquo;, combined with impaired swallowing can lead to cachexia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]. Tongue and lip biting are characteristic features [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/40\">",
"       40",
"      </a>",
"      ]; patients may learn to put a handkerchief or towel in the mouth to prevent such self-mutilation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/41\">",
"       41",
"      </a>",
"      ]. Limb dystonias may also be present.",
"      <br/>",
"      <br/>",
"      Vocal tics consisting of gasping, sighing, clicking, whistling, blowing, sucking, grunting, and humming occur in two-thirds of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/37,42\">",
"       37,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A \"frontal lobe syndrome\" has been described in these patients, which may include social and sexual disinhibition, impaired decision-making capacity, impaired insight, obsessive compulsive tendencies, and self-neglect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Anxiety, paranoia, aggression, and even frank psychosis have also been described. Suicidal behavior may also occur. The neuropsychiatric symptoms may precede the movement disorder, particularly in retrospect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33,44\">",
"       33,44",
"      </a>",
"      ]. In such cases, the later appearance of a movement disorder may be wrongly attributed to neuroleptic drug administration and delay diagnosis.",
"      <br/>",
"      <br/>",
"      Impaired memory and executive functioning are common but not invariable.",
"     </li>",
"     <li>",
"      Dysarthria is common and may be a presenting symptom [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/45\">",
"       45",
"      </a>",
"      ]. Some patients become mute.",
"     </li>",
"     <li>",
"      Generalized tonic-clonic or partial complex seizures occur in half of patients; some patients develop epilepsy as their initial clinical manifestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/46\">",
"       46",
"      </a>",
"      ]. In many patients, seizures are found to emanate from one or both temporal lobes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/47-49\">",
"       47-49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neuropathy is mild and often subclinical, manifesting with distal muscle wasting, depressed distal deep tendon reflexes, and mild sensory abnormalities, particularly impaired vibration sense. At least one patient has been described with a motor neuron disease-like presentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subtle eye movement abnormalities may occur, such as impaired upgaze [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/51,52\">",
"       51,52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once symptoms develop, significant disability may accrue in just a few years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/40\">",
"     40",
"    </a>",
"    ]. Death occurs between the ages of 28 to 61 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88328413\">",
"    <span class=\"h2\">",
"     Laboratory and test findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical laboratory and test findings include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acanthocytes usually constitute 5 to 50 percent of the circulating RBC population. Acanthocytes may appear late in the course of the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/53\">",
"       53",
"      </a>",
"      ] and may be absent altogether [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/41\">",
"       41",
"      </a>",
"      ]. In order to improve the yield of finding acanthocytes in this disease, one recommended technique is to dilute the sample 1:1 with heparinized normal saline, incubate the specimen for 5 to 30 minutes, fix it with Karnofsky solution, and view the cells under Nomarski optics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most patients have elevated serum CK levels (300-3000",
"      <span class=\"nowrap\">",
"       U/L).",
"      </span>",
"      Less commonly, LDH, AST, and ALT serum levels may be increased. The cause of the CK elevations is not clear.",
"     </li>",
"     <li>",
"      MR imaging may show atrophy of the caudate head and dilatation of the anterior horns of the lateral ventricles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/55-58\">",
"       55-58",
"      </a>",
"      ]. In one patient, susceptibility-weighted MR imaging demonstrated attenuation in the caudates bilaterally, consistent with iron deposition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/59\">",
"       59",
"      </a>",
"      ]. Functional neuroimaging studies also support the striatum as an area of primary dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/60\">",
"       60",
"      </a>",
"      ]. CT imaging may only show mild cerebral atrophy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The interictal EEG typically shows nonspecific findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nerve conduction studies reveal features suggestive of a sensory axonal neuropathy with low SNAP amplitudes but normal conduction velocities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/51\">",
"       51",
"      </a>",
"      ]. Motor nerve conduction studies may be entirely normal. Electromyography reveals evidence of chronic denervation with reinnervation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The muscle biopsy shows predominantly neurogenic features including small angulated fibers and grouped atrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/62\">",
"     62",
"    </a>",
"    ]. An increase of central nuclei and split fibers have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/63\">",
"     63",
"    </a>",
"    ]. Peripheral nerve biopsies have shown a loss of predominantly large diameter fibers with features of nerve regeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/51\">",
"     51",
"    </a>",
"    ]. Biopsies of the muscle or nerve are not required for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1983013\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorea-acanthocytosis and McLeod syndrome are clinically indistinguishable, but the McLeod blood group phenotype differentiates McLeod syndrome from chorea-acanthocytosis. (See",
"    <a class=\"local\" href=\"#H1983242\">",
"     'Mcleod syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Huntington disease and Huntington disease-like 2 can also present with chorea or parkinsonism, along with cognitive and behavioral changes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Atrophy of the caudate nucleus is shared by these entities. Prominent orofacial dyskinesias causing dysarthria and dysphagia suggest chorea-acanthocytosis. The autosomal pattern of inheritance, the phenomenon of anticipation (earlier disease onset in successive generations), lack of serum CK enzyme elevations and distal muscle wasting, and significant cortical atrophy help distinguish Huntington disease and Huntington disease-like 2 from chorea-acanthocytosis. Finally, these two disorders may be diagnosed by molecular genetic analysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29832?source=see_link\">",
"     \"Huntington disease: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H4519438\">",
"     'Huntington Disease-Like 2'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Wilson disease is an autosomal recessive disease that may present with hepatic, neurologic, or psychiatric symptoms almost always before age 50 years. Patients with Wilson disease may present with a variety of abnormal movements, including tremors, chorea, choreoathetosis, or parkinsonian features. An important feature that distinguishes chorea-acanthocytosis from Wilson's disease is the absence of liver disease. Low serum copper and ceruloplasmin levels along with increased urinary copper excretion are specific to Wilson disease. Testing for mutations in the gene responsible for Wilson disease (ATP7B) is commercially available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13018?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of Wilson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pantothenate kinase-associated neurodegeneration (PKAN; also known as Hallervorden-Spatz syndrome) is an autosomal recessive disease characterized by progressive dystonia and pigmentary retinopathy before the age of 10 years. Atypical forms of the disease may present at a later age. The MRI finding &ldquo;eye of the tiger&rdquo; may be diagnostic in some patients. (See",
"    <a class=\"local\" href=\"#H4519453\">",
"     'Pantothenate kinase-associated neurodegeneration'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/36/15943?source=see_link&amp;anchor=H10#H10\">",
"     \"Bradykinetic movement disorders in children\", section on 'Neurodegeneration with brain iron accumulation'",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1983027\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;No formal diagnostic criteria for chorea-acanthocytosis exist. The diagnosis is based on recognizing the characteristic clinical features with peripheral acanthocytosis and normal lipid studies. Particularly in male patients, testing for the McLeod blood phenotype should be considered because McLeod syndrome may present indistinguishably from chorea-acanthocytosis.",
"   </p>",
"   <p>",
"    Because of the gene's expression in RBCs, the western blot of a patient's erythrocyte membranes with antichorein antisera may become a useful initial diagnostic test (",
"    <a class=\"external\" href=\"file://www.euro-hd.net/html/na/network/docs/chorein-wb-info.pdf\">",
"     file://www.euro-hd.net/html/na/network/docs/chorein-wb-info.pdf",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/32\">",
"     32",
"    </a>",
"    ]. Follow-up mutational analysis of the VPS13A gene can be performed, however, this is challenging due to the large size of the gene and the heterogeneity of mutation sites. Molecular genetic testing for VPS13A mutations is not widely available; one center reportedly performs this analysis (",
"    <a class=\"external\" href=\"file://www.mgz-muenchen.de/\">",
"     file://www.mgz-muenchen.de",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1983076\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;No curative or disease modifying treatment for chorea-acanthocytosis currently exists. Treatment is aimed at symptom management. A multidisciplinary approach to disease management is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The movement disorder symptoms are most challenging to manage. Physical and occupational therapy can provide assistance. Strategies employed in other conditions may be tried in patients with chorea-acanthocytosis (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12105?source=see_link\">",
"       \"Treatment of dystonia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39385?source=see_link&amp;anchor=H4#H4\">",
"       \"Huntington disease: Management\", section on 'Chorea'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=see_link\">",
"       \"Pharmacologic treatment of Parkinson disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32105?source=see_link&amp;anchor=H5#H5\">",
"       \"Surgical treatment of Parkinson disease\", section on 'Deep brain stimulation'",
"      </a>",
"      .). As examples:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Orofacial dystonias may be ameliorated by botulinum toxin injections into overactive muscles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/40,66\">",
"       40,66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a single case report, the atypical antipsychotic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      dramatically, but temporarily, ameliorated chorea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Deep brain stimulation and other neurosurgical procedures have been tried in a handful of cases. In one individual, bilateral thalamic brain stimulation did significantly reduce trunk spasms, and the benefit lasted for one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/68\">",
"       68",
"      </a>",
"      ]. Bilateral stimulation of the globus pallidus interna have been helpful in some cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/69-71\">",
"       69-71",
"      </a>",
"      ], but not in others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should have regular evaluations by speech and language pathology. Swallowing function should be monitored; feeding assistance and gastrostomy may become necessary. When speech communication becomes difficult, an augmentative communications specialist can assist with devising a computer-controlled speech system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seizures are typically controlled with standard antiepileptic drug regimens. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link\">",
"       \"Overview of the management of epilepsy in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link\">",
"       \"Initial treatment of epilepsy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While uncommon, cardiomyopathy has been described in chorea-acanthocytosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. An electrocardiogram and screening transthoracic echocardiogram is recommended in these patients during the initial evaluation. Early consultation with cardiology is recommended if evidence of a cardiomyopathy is found.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic testing may useful, but because the disease presents later in adulthood, parents of affected individuals are relatively unlikely to have more children. Siblings have a one in four chance of inheriting the disease; but children of affected individuals do not manifest the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1983242\">",
"    <span class=\"h1\">",
"     MCLEOD SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;McLeod syndrome is an X-linked disorder which is caused by mutations in the XK gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/74-77\">",
"     74-77",
"    </a>",
"    ]. The function of the XK protein is not known, but it shares homologies with the ced-8 protein in C. elegans. Ced-8 has an important role in caspase-mediated cell death (apoptosis). The XK protein is expressed in many tissues, including erythroid tissues, the brain, and muscle. In red blood cells, the XK protein is linked to the Kell glycoprotein via a single disulfide bond. The two proteins are thought to form a functional complex. The cellular functions of this complex are not well understood. In instances when the XK protein is not expressed (as in McLeod syndrome), the Kell glycoprotein is absent or very reduced.",
"   </p>",
"   <p>",
"    Female carriers may manifest subtle signs of McLeod syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"     33",
"    </a>",
"    ]. Skewed inactivation of the X chromosome not harboring the mutation is probably responsible for disease manifestations in these carriers.",
"   </p>",
"   <p>",
"    McLeod syndrome is quite rare, with an estimated few hundred cases worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1983083\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;This disorder usually presents in young adulthood with choreiform movements, cognitive impairment, psychiatric symptoms, (often subclinical) neuromuscular findings, and acanthocytosis. Cardiomyopathy is an important systemic manifestation of the disorder.",
"   </p>",
"   <p>",
"    The age of onset varies from 18 to 61 years. The symptoms tend to progress over decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33,78\">",
"     33,78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      About one-third of patients present with chorea. Restlessness and small amplitude involuntary movements of the ankles and fingers may be seen in early stages of the disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/79\">",
"       79",
"      </a>",
"      ]. Later, choreiform movements of the limbs appear in up 95 percent of the patients. Involuntary tic-like facial movements are also common, but orofacial dystonias are atypical [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Up to 80 percent of patients develop psychopathology over time [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/81-85\">",
"       81-85",
"      </a>",
"      ]. Anxiety and depression and \"emotional lability\" are common; some patients develop obsessive compulsive disorder or psychosis. Psychometric tests have revealed problems with memory and executive function.",
"     </li>",
"     <li>",
"      Almost all patients have absent ankle tendon reflexes and generalized areflexia is common. It is uncommon for patients to have complaints about sensation. Slowly progressive muscle weakness and atrophy is common, but only about half of patients will ultimately develop weakness that is clinically significant.",
"     </li>",
"     <li>",
"      Two-thirds of patients have evidence of cardiac disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/86\">",
"       86",
"      </a>",
"      ]. Cardiomyopathy and cardiac arrhythmias (atrial fibrillation and atrial flutter) have been described.",
"     </li>",
"     <li>",
"      Seizures occur in about half of patients.",
"     </li>",
"     <li>",
"      McLeod syndrome may be part of a contiguous gene syndrome on the X chromosome including chronic granulomatous disease, Duchenne muscular dystrophy or X-linked retinitis pigmentosa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10826?source=see_link\">",
"       \"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/16/1290?source=see_link\">",
"       \"Clinical features and diagnosis of Duchenne and Becker muscular dystrophy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19896?source=see_link\">",
"       \"Retinitis pigmentosa: Clinical presentation and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The age of death ranges from 31 to 69 years, with a mean age of 53 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/51,81,82\">",
"     51,81,82",
"    </a>",
"    ]. Tachyarrhythmias related to the cardiomyopathy are thought to be a common cause of premature death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88328858\">",
"    <span class=\"h2\">",
"     Laboratory and test findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;McLeod blood phenotype is sometimes identified in asymptomatic patients or carriers before the development of neurologic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. A weak reaction to Kell antisera and no reaction to XK antisera establish the diagnosis of the McLeod blood phenotype.",
"   </p>",
"   <p>",
"    In addition to the McLeod blood phenotype, laboratory and test findings include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acanthocytes constitute 3 to 40 percent of the RBC population. A compensated hemolysis is present.",
"     </li>",
"     <li>",
"      Elevated serum CK levels (up to 4000",
"      <span class=\"nowrap\">",
"       U/l)",
"      </span>",
"      have been described in every patient to date. Patients are susceptible to rhabdomyolysis, particularly in the setting of other risk factors, such as neuroleptic medication use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/91\">",
"       91",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/33/10777?source=see_link\">",
"       \"Causes of rhabdomyolysis\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      Progressive atrophy of the caudate nucleus is the most common finding on MR imaging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/82,92\">",
"       82,92",
"      </a>",
"      ]. Abnormalities on T2-weighted images have been described in the basal ganglia, specifically increased T2 signal in the lateral putamen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nerve conduction studies may show low amplitudes for motor and sensory responses but normal conduction velocities, suggesting an axonal neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/93\">",
"       93",
"      </a>",
"      ]. Electromyography has shows predominantly neurogenic features, although myopathic findings have also been described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Muscle biopsy specimens may show neurogenic (fiber-type grouping) and myopathic (increased central nuclei, increased fiber size variation, and rare degenerating fibers) features. Type 1 fiber predominance and type 2 fiber atrophy also have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1983132\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorea-acanthocytosis and McLeod syndrome patients present with similar clinical findings. Parkinsonism occurs in some patients with chorea-acanthocytosis but is rare in McLeod syndrome. The prominent orofacial dystonias of the former disease are also not usual in McLeod syndrome. (See",
"    <a class=\"local\" href=\"#H1982957\">",
"     'Chorea-acanthocytosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The differential diagnosis of McLeod syndrome overlaps substantively with chorea-acanthocytosis and includes Huntington disease, Huntington disease-like 2, pantothenate kinase-associated neurodegeneration (PKAN; also called Hallervorden-Spatz syndrome), and Wilson disease (see",
"    <a class=\"local\" href=\"#H1983013\">",
"     'Differential diagnosis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The McLeod blood phenotype separates McLeod syndrome from other disorders (see",
"    <a class=\"local\" href=\"#H88328858\">",
"     'Laboratory and test findings'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1983146\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis rests on the combination of clinical findings, acanthocytosis, and the McLeod blood phenotype. A weak reaction to Kell antisera and no reaction to XK antisera establish the diagnosis of the McLeod blood phenotype. Molecular genetic testing for mutations of the XK gene is not currently commercially available. The percentage of individuals with the McLeod blood phenotype who never present with neurologic manifestations is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1983188\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no curative treatment or disease modifying therapy for McLeod Syndrome. Current treatment is aimed at symptom management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A screening ECG and echocardiogram should be obtained during the initial work-up. Many of these patients will need to be followed by cardiology. Patients at risk for cardiogenic embolism should be anticoagulated. Some suggest that asymptomatic carriers of the McLeod blood phenotype should also be screened for cardiac disease.",
"     </li>",
"     <li>",
"      Medications used to treat chorea in other syndromes can be tried. In single cases, hyperkinetic movements have responded to tiapride and sulpiride but not",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/82\">",
"       82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39385?source=see_link&amp;anchor=H4#H4\">",
"       \"Huntington disease: Management\", section on 'Chorea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizures can be well controlled with a variety of antiepileptic drugs. Specifically,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      have been used with success in these patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/82\">",
"       82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=see_link\">",
"       \"Initial treatment of epilepsy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptom-appropriate psychotropic drugs should be used as needed; however, psychiatric symptoms may be resistant to standard pharmacotherapy. One such patient responded to electroconvulsive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic counseling is appropriate. Affected males will pass on the mutation to all of their daughters, whose sons will have a one in two chance of developing the syndrome and whose daughters will have a one in two chance of being carriers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"       33",
"      </a>",
"      ]. Female carrier heterozygotes rarely develop a neurological syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4519453\">",
"    <span class=\"h1\">",
"     PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pantothenate kinase-associated neurodegeneration (PKAN), formerly known as Hallervorden-Spatz disease, is an autosomal recessive disorder; most cases are caused by mutations in the gene encoding pantothenate kinase 2 (PANK2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/96-98\">",
"     96-98",
"    </a>",
"    ]. PANK2 catalyses the rate limiting step in the synthesis of coenzyme A from vitamin B5. PKAN is included in a group of disorders known as neurodegeneration with brain iron accumulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/36/15943?source=see_link&amp;anchor=H10#H10\">",
"     \"Bradykinetic movement disorders in children\", section on 'Neurodegeneration with brain iron accumulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Classic PKAN present in the first decade of life with extrapyramidal signs including orofacial and limb dystonia, dysarthria, rigidity, and choreoathetosis. Retinopathy, spasticity, and cognitive decline are common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/98\">",
"     98",
"    </a>",
"    ]. Acanthocytosis occurs in just 8 to 10 percent. Less commonly, patients may present later in life (in the second decade) with more prominent rigidity and a slower progression. In such patients, the clinical syndrome overlaps with juvenile onset Huntington disease, Huntington disease-like 2, and chorea-acanthocytosis.",
"   </p>",
"   <p>",
"    On brain MRI, iron deposition in the globus pallidus creates a hallmark \"eye of the tiger\" sign in these patients, which can be diagnostic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/98\">",
"     98",
"    </a>",
"    ]. Sequence analysis of the PANK2 gene is commercially available to confirm the diagnosis.",
"   </p>",
"   <p>",
"    This disorder is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/36/15943?source=see_link&amp;anchor=H10#H10\">",
"     \"Bradykinetic movement disorders in children\", section on 'Neurodegeneration with brain iron accumulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4519438\">",
"    <span class=\"h1\">",
"     HUNTINGTON DISEASE-LIKE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Huntington disease-like 2 (HDL2) is a rare autosomal dominant disorder caused by CTG trinucleotide repeat mutations in the junctophilin-3 gene (JPH3) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. Apparently unaffected individuals with repeats in the JPH3 gene may develop the disease later. HDL2 has been reported mainly in patients of African ancestry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/102\">",
"     102",
"    </a>",
"    ], although it has also been reported in a patient of apparent European ancestry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/103\">",
"     103",
"    </a>",
"    ]. It is rare disorder with approximately 25 pedigrees and 40 affected individuals reported as of a 2012 publication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This disease presents in midlife (age 29 to 41 years) with a progressive movement disorder, along with dementia and psychiatric disturbances (depression, apathy, irritability) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/100,104\">",
"     100,104",
"    </a>",
"    ]. The movement disorder may be one of predominant parkinsonian accompanied by rigidity, or chorea with abnormal eye movements. Neither seizures nor peripheral nerve or muscle problems have been reported in HDL2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"     33",
"    </a>",
"    ]. Death occurs 10 to 20 years after presentation.",
"   </p>",
"   <p>",
"    Acanthocytosis has been reported in some affected individuals, but this is not universal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/105\">",
"     105",
"    </a>",
"    ]. Brain MRI findings are similar to those of Huntington disease with prominent atrophy of the caudate and cerebral cortex.",
"   </p>",
"   <p>",
"    The clinical presentation of HDL2 is similar to juvenile onset Huntington disease and also overlaps with chorea-acanthocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33833/abstract/65,106\">",
"     65,106",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1983013\">",
"     'Differential diagnosis'",
"    </a>",
"    above.) The diagnosis is made by molecular genetic testing.",
"   </p>",
"   <p>",
"    Treatment is symptomatic and is similar to that of Huntington disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39385?source=see_link\">",
"     \"Huntington disease: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic counseling is appropriate as siblings will have a 50 percent risk of developing the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88328894\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroacanthocytosis refers to a group of rare diseases that share central nervous system degeneration, neuromuscular manifestations, and acanthocytosis (",
"    <a class=\"graphic graphic_picture graphicRef80080 \" href=\"mobipreview.htm?14/26/14760\">",
"     picture 1",
"    </a>",
"    ) on a peripheral blood smear:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abetalipoproteinemia is an autosomal recessive disorder caused by mutations in the microsomal triglyceride transfer protein. The neurologic manifestations result from the inability to absorb and transport vitamin E and include progressive ataxia, sensory-motor neuropathy, and vision impairment with retinitis pigmentosa. The diagnosis is made in the setting of the typical clinical findings accompanied by laboratory findings of acanthocytosis, very low triglyceride and total cholesterol levels, and absent beta-lipoproteins. Neurologic manifestations can be prevented and partially reversed with the administration of vitamin E, 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day along with other fat soluble vitamins. (See",
"      <a class=\"local\" href=\"#H1983214\">",
"       'Abetalipoproteinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chorea-acanthocytosis is a rare autosomal recessive disorder characterized by the onset in young adulthood of chorea",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parkinsonism, oro-lingual-facial dystonias, tics, social disinhibition, seizures, areflexia, and distal muscle wasting. No formal diagnostic criteria for chorea-acanthocytosis exist; the disorder is suspected on the basis of the clinical symptoms and the presence of acanthocytosis. Genetic testing confirms the diagnosis, but is not widely available. No curative or disease modifying treatment for chorea-acanthocytosis currently exists. Treatment is aimed at symptom management. (See",
"      <a class=\"local\" href=\"#H1982957\">",
"       'Chorea-acanthocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      McLeod syndrome is an X-linked recessive disorder that has a similar clinical presentation to chorea-acanthocytosis. Cardiomyopathy is an important systemic manifestation of the disorder. A specific test finding is the McLeod blood phenotype. Management includes symptomatic treatments, cardiologic screening and followup, and genetic counselling. (See",
"      <a class=\"local\" href=\"#H1983242\">",
"       'Mcleod syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pantothenate kinase-associated neurodegeneration (PKAN, Hallervorden-Spatz disease) is an autosomal recessive disorder caused by mutations in the gene encoding pantothenate kinase 2. It typically presents in childhood with orofacial and limb dystonia, choreaoathetosis and spasticity. Retinopathy and cognitive decline are also common but not invariable. (See",
"      <a class=\"local\" href=\"#H4519453\">",
"       'Pantothenate kinase-associated neurodegeneration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Huntington disease-like 2 is an autosomal dominant disorder caused by a trinucleotide repeat expansion in JPH3. It mimics juvenile onset Huntington disease with onset in midlife of parkinsonism and dystonia or chorea, accompanied by progressive dementia. It is diagnosed by molecular genetic testing. Similar to HD, management focuses on symptoms. (See",
"      <a class=\"local\" href=\"#H4519438\">",
"       'Huntington Disease-Like 2'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/1\">",
"      Wetterau JR, Aggerbeck LP, Bouma ME, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992; 258:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/2\">",
"      Sharp D, Blinderman L, Combs KA, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993; 365:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/3\">",
"      Shoulders CC, Brett DJ, Bayliss JD, et al. Abetalipoproteinemia is caused by defects of the gene encoding the 97 kDa subunit of a microsomal triglyceride transfer protein. Hum Mol Genet 1993; 2:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/4\">",
"      Rampoldi L, Danek A, Monaco AP. Clinical features and molecular bases of neuroacanthocytosis. J Mol Med (Berl) 2002; 80:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/5\">",
"      Kayden HJ, Traber MG. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J Lipid Res 1993; 34:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/6\">",
"      BASSEN FA, KORNZWEIG AL. Malformation of the erythrocytes in a case of atypical retinitis pigmentosa. Blood 1950; 5:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/7\">",
"      Zamel R, Khan R, Pollex RL, Hegele RA. Abetalipoproteinemia: two case reports and literature review. Orphanet J Rare Dis 2008; 3:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/8\">",
"      Lowry NJ, Taylor MJ, Belknapp W, Logan WJ. Electrophysiological studies in five cases of abetalipoproteinemia. Can J Neurol Sci 1984; 11:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/9\">",
"      Brin MF, Pedley TA, Lovelace RE, et al. Electrophysiologic features of abetalipoproteinemia: functional consequences of vitamin E deficiency. Neurology 1986; 36:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/10\">",
"      Di Filippo M, Cr&eacute;halet H, Samson-Bouma ME, et al. Molecular and functional analysis of two new MTTP gene mutations in an atypical case of abetalipoproteinemia. J Lipid Res 2012; 53:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/11\">",
"      Illingworth DR, Kenny TA, Orwoll ES. Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J Clin Endocrinol Metab 1982; 54:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/12\">",
"      Fogel BL, Perlman S. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias. Lancet Neurol 2007; 6:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/13\">",
"      Ouahchi K, Arita M, Kayden H, et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. Nat Genet 1995; 9:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/14\">",
"      Mariotti C, Gellera C, Rimoldi M, et al. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurol Sci 2004; 25:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/15\">",
"      Young SG, Bertics SJ, Curtiss LK, Witztum JL. Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia. J Clin Invest 1987; 79:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/16\">",
"      Young SG, Northey ST, McCarthy BJ. Low plasma cholesterol levels caused by a short deletion in the apolipoprotein B gene. Science 1988; 241:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/17\">",
"      Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res 2003; 44:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/18\">",
"      Tarugi P, Averna M. Hypobetalipoproteinemia: genetics, biochemistry, and clinical spectrum. Adv Clin Chem 2011; 54:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/19\">",
"      Higgins JJ, Patterson MC, Papadopoulos NM, et al. Hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP syndrome). Neurology 1992; 42:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/20\">",
"      Orrell RW, Amrolia PJ, Heald A, et al. Acanthocytosis, retinitis pigmentosa, and pallidal degeneration: a report of three patients, including the second reported case with hypoprebetalipoproteinemia (HARP syndrome). Neurology 1995; 45:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/21\">",
"      Ching KH, Westaway SK, Gitschier J, et al. HARP syndrome is allelic with pantothenate kinase-associated neurodegeneration. Neurology 2002; 58:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/22\">",
"      Muller DP, Lloyd JK, Bird AC. Long-term management of abetalipoproteinaemia. Possible role for vitamin E. Arch Dis Child 1977; 52:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/23\">",
"      Muller DP, Lloyd JK, Wolff OH. The role of vitamin E in the treatment of the neurological features of abetalipoproteinaemia and other disorders of fat absorption. J Inherit Metab Dis 1985; 8 Suppl 1:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/24\">",
"      Runge P, Muller DP, McAllister J, et al. Oral vitamin E supplements can prevent the retinopathy of abetalipoproteinaemia. Br J Ophthalmol 1986; 70:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/25\">",
"      Hegele RA, Angel A. Arrest of neuropathy and myopathy in abetalipoproteinemia with high-dose vitamin E therapy. Can Med Assoc J 1985; 132:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/26\">",
"      Berson EL. Nutrition and retinal degenerations. Int Ophthalmol Clin 2000; 40:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/27\">",
"      Kayden HJ, Hatam LJ, Traber MG. The measurement of nanograms of tocopherol from needle aspiration biopsies of adipose tissue: normal and abetalipoproteinemic subjects. J Lipid Res 1983; 24:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/28\">",
"      Chowers I, Banin E, Merin S, et al. Long-term assessment of combined vitamin A and E treatment for the prevention of retinal degeneration in abetalipoproteinaemia and hypobetalipoproteinaemia patients. Eye (Lond) 2001; 15:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/29\">",
"      Rampoldi L, Dobson-Stone C, Rubio JP, et al. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet 2001; 28:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/30\">",
"      Ueno S, Maruki Y, Nakamura M, et al. The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat Genet 2001; 28:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/31\">",
"      Danek A, Bader B, Velayos-Baeza A, Walker RH. Autosomal recessive transmission of chorea-acanthocytosis confirmed. Acta Neuropathol 2012; 123:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/32\">",
"      Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol 2004; 56:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/33\">",
"      Jung HH, Danek A, Walker RH. Neuroacanthocytosis syndromes. Orphanet J Rare Dis 2011; 6:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/34\">",
"      Peppard RF, Lu CS, Chu NS, et al. Parkinsonism with neuroacanthocytosis. Can J Neurol Sci 1990; 17:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/35\">",
"      Bostantjopoulou S, Katsarou Z, Kazis A, Vadikolia C. Neuroacanthocytosis presenting as parkinsonism. Mov Disord 2000; 15:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/36\">",
"      Schneider SA, Lang AE, Moro E, et al. Characteristic head drops and axial extension in advanced chorea-acanthocytosis. Mov Disord 2010; 25:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/37\">",
"      Wyszynski B, Merriam A, Medalia A, Lawrence C. Choreoacanthocytosis: Report of a case with psychiatric features. Neuropsychol Behav Neurol 1989; 2:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/38\">",
"      Aminoff MJ. Acanthocytosis and neurological disease. Brain 1972; 95:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/39\">",
"      Bader B, Walker RH, Vogel M, et al. Tongue protrusion and feeding dystonia: a hallmark of chorea-acanthocytosis. Mov Disord 2010; 25:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/40\">",
"      Aasly J, Skandsen T, R&oslash; M. Neuroacanthocytosis--the variability of presenting symptoms in two siblings. Acta Neurol Scand 1999; 100:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/41\">",
"      Malandrini A, Fabrizi GM, Palmeri S, et al. Choreo-acanthocytosis like phenotype without acanthocytes: clinicopathological case report. A contribution to the knowledge of the functional pathology of the caudate nucleus. Acta Neuropathol 1993; 86:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/42\">",
"      Saiki S, Hirose G, Sakai K, et al. Chorea-acanthocytosis associated with Tourettism. Mov Disord 2004; 19:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/43\">",
"      Walterfang M, Evans A, Looi JC, et al. The neuropsychiatry of neuroacanthocytosis syndromes. Neurosci Biobehav Rev 2011; 35:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/44\">",
"      Walterfang M, Yucel M, Walker R, et al. Adolescent obsessive compulsive disorder heralding chorea-acanthocytosis. Mov Disord 2008; 23:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/45\">",
"      Alonso ME, Teixeira F, Jimenez G, Escobar A. Chorea-acanthocytosis: report of a family and neuropathological study of two cases. Can J Neurol Sci 1989; 16:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/46\">",
"      Al-Asmi A, Jansen AC, Badhwar A, et al. Familial temporal lobe epilepsy as a presenting feature of choreoacanthocytosis. Epilepsia 2005; 46:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/47\">",
"      Tiftikcioglu BI, Dericioglu N, Saygi S. Focal seizures originating from the left temporal lobe in a case with chorea-acanthocytosis. Clin EEG Neurosci 2006; 37:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/48\">",
"      Bader B, Vollmar C, Ackl N, et al. Bilateral temporal lobe epilepsy confirmed with intracranial EEG in chorea-acanthocytosis. Seizure 2011; 20:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/49\">",
"      Scheid R, Bader B, Ott DV, et al. Development of mesial temporal lobe epilepsy in chorea-acanthocytosis. Neurology 2009; 73:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/50\">",
"      Neutel D, Miltenberger-Miltenyi G, Silva I, de Carvalho M. Chorea-acanthocytosis presenting as motor neuron disease. Muscle Nerve 2012; 45:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/51\">",
"      Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991; 114 ( Pt 1A):13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/52\">",
"      Gradstein L, Danek A, Grafman J, Fitzgibbon EJ. Eye movements in chorea-acanthocytosis. Invest Ophthalmol Vis Sci 2005; 46:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/53\">",
"      Sorrentino G, De Renzo A, Miniello S, et al. Late appearance of acanthocytes during the course of chorea-acanthocytosis. J Neurol Sci 1999; 163:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/54\">",
"      Feinberg TE, Cianci CD, Morrow JS, et al. Diagnostic tests for choreoacanthocytosis. Neurology 1991; 41:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/55\">",
"      Kutcher JS, Kahn MJ, Andersson HC, Foundas AL. Neuroacanthocytosis masquerading as Huntington's disease: CT/MRI findings. J Neuroimaging 1999; 9:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/56\">",
"      Okamoto K, Ito J, Furusawa T, et al. CT and MR findings of neuroacanthocytosis. J Comput Assist Tomogr 1997; 21:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/57\">",
"      Walterfang M, Looi JC, Styner M, et al. Shape alterations in the striatum in chorea-acanthocytosis. Psychiatry Res 2011; 192:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/58\">",
"      Henkel K, Danek A, Grafman J, et al. Head of the caudate nucleus is most vulnerable in chorea-acanthocytosis: a voxel-based morphometry study. Mov Disord 2006; 21:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/59\">",
"      Lee JH, Lee SM, Baik SK. Demonstration of striatopallidal iron deposition in chorea-acanthocytosis by susceptibility-weighted imaging. J Neurol 2011; 258:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/60\">",
"      M&uuml;ller-Vahl KR, Berding G, Emrich HM, Peschel T. Chorea-acanthocytosis in monozygotic twins: clinical findings and neuropathological changes as detected by diffusion tensor imaging, FDG-PET and (123)I-beta-CIT-SPECT. J Neurol 2007; 254:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/61\">",
"      Hori A, Kazukawa S, Nakamura I, Endo M. Electroencephalographic findings in neuroacanthocytosis. Electroencephalogr Clin Neurophysiol 1985; 61:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/62\">",
"      Saiki S, Sakai K, Murata KY, et al. Primary skeletal muscle involvement in chorea-acanthocytosis. Mov Disord 2007; 22:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/63\">",
"      Limos LC, Ohnishi A, Sakai T, et al. \"Myopathic\" changes in chorea-acanthocytosis. Clinical and histopathological studies. J Neurol Sci 1982; 55:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/64\">",
"      Gold MM, Shifteh K, Bello JA, et al. Chorea-acanthocytosis: a mimicker of Huntington disease case report and review of the literature. Neurologist 2006; 12:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/65\">",
"      Saiki S, Sakai K, Saiki M, Hirose G. Huntington's disease-like 2 can present as chorea-acanthocytosis. Neurology 2004; 63:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/66\">",
"      Sokolov E, Schneider SA, Bain PG. Chorea-acanthocytosis. Pract Neurol 2012; 12:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/67\">",
"      Wihl G, Volkmann J, Allert N, et al. Deep brain stimulation of the internal pallidum did not improve chorea in a patient with neuro-acanthocytosis. Mov Disord 2001; 16:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/68\">",
"      Burbaud P, Rougier A, Ferrer X, et al. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. Mov Disord 2002; 17:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/69\">",
"      Shin H, Ki CS, Cho AR, et al. Globus pallidus interna deep brain stimulation improves chorea and functional status in a patient with chorea-acanthocytosis. Stereotact Funct Neurosurg 2012; 90:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/70\">",
"      Li P, Huang R, Song W, et al. Deep brain stimulation of the globus pallidus internal improves symptoms of chorea-acanthocytosis. Neurol Sci 2012; 33:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/71\">",
"      Ruiz PJ, Ayerbe J, Bader B, et al. Deep brain stimulation in chorea acanthocytosis. Mov Disord 2009; 24:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/72\">",
"      Lossos A, Dobson-Stone C, Monaco AP, et al. Early clinical heterogeneity in choreoacanthocytosis. Arch Neurol 2005; 62:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/73\">",
"      Kageyama Y, Matsumoto K, Ichikawa K, et al. A new phenotype of chorea-acanthocytosis with dilated cardiomyopathy and myopathy. Mov Disord 2007; 22:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/74\">",
"      Ho M, Chelly J, Carter N, et al. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 1994; 77:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/75\">",
"      Dubielecka PM, Hwynn N, Sengun C, et al. Two McLeod patients with novel mutations in XK. J Neurol Sci 2011; 305:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/76\">",
"      Arnaud L, Salachas F, Lucien N, et al. Identification and characterization of a novel XK splice site mutation in a patient with McLeod syndrome. Transfusion 2009; 49:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/77\">",
"      Singleton BK, Green CA, Renaud S, et al. McLeod syndrome resulting from a novel XK mutation. Br J Haematol 2003; 122:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/78\">",
"      Hewer E, Danek A, Schoser BG, et al. McLeod myopathy revisited: more neurogenic and less benign. Brain 2007; 130:3285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/79\">",
"      Danek A, Tison F, Rubio J, et al. The chorea of McLeod syndrome. Mov Disord 2001; 16:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/80\">",
"      Gantenbein AR, Damon-Perri&egrave;re N, Bohlender JE, et al. Feeding dystonia in McLeod syndrome. Mov Disord 2011; 26:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/81\">",
"      Malandrini A, Fabrizi GM, Truschi F, et al. Atypical McLeod syndrome manifested as X-linked chorea-acanthocytosis, neuromyopathy and dilated cardiomyopathy: report of a family. J Neurol Sci 1994; 124:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/82\">",
"      Danek A, Rubio JP, Rampoldi L, et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol 2001; 50:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/83\">",
"      Jung HH, Hergersberg M, Kneifel S, et al. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol 2001; 49:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/84\">",
"      V&aacute;zquez MJ, Mart&iacute;nez MC. Electroconvulsive therapy in neuroacanthocytosis or McLeod syndrome. J ECT 2009; 25:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/85\">",
"      Jung HH, Haker H. Schizophrenia as a manifestation of X-linked Mcleod-Neuroacanthocytosis syndrome. J Clin Psychiatry 2004; 65:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/86\">",
"      Oechslin E, Kaup D, Jenni R, Jung HH. Cardiac abnormalities in McLeod syndrome. Int J Cardiol 2009; 132:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/87\">",
"      Peng J, Redman CM, Wu X, et al. Insights into extensive deletions around the XK locus associated with McLeod phenotype and characterization of two novel cases. Gene 2007; 392:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/88\">",
"      Starling A, Schlesinger D, Kok F, et al. A family with McLeod syndrome and calpainopathy with clinically overlapping diseases. Neurology 2005; 65:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/89\">",
"      Walker RH, Danek A, Uttner I, et al. McLeod phenotype without the McLeod syndrome. Transfusion 2007; 47:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/90\">",
"      Wendel S, Font&atilde;o-Wendel R, Levi JE, et al. A McLeod phenotype detected by random screening for K:-4 [Kp(b-)] blood donors in Brazil. Transfusion 2004; 44:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/91\">",
"      Jung HH, Brandner S. Malignant McLeod myopathy. Muscle Nerve 2002; 26:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/92\">",
"      Valko PO, H&auml;nggi J, Meyer M, Jung HH. Evolution of striatal degeneration in McLeod syndrome. Eur J Neurol 2010; 17:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/93\">",
"      Wada M, Kimura M, Daimon M, et al. An unusual phenotype of McLeod syndrome with late onset axonal neuropathy. J Neurol Neurosurg Psychiatry 2003; 74:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/94\">",
"      Swash M, Schwartz MS, Carter ND, et al. Benign X-linked myopathy with acanthocytes (McLeod syndrome). Its relationship to X-linked muscular dystrophy. Brain 1983; 106 (Pt 3):717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/95\">",
"      Witt TN, Danek A, Reiter M, et al. McLeod syndrome: a distinct form of neuroacanthocytosis. Report of two cases and literature review with emphasis on neuromuscular manifestations. J Neurol 1992; 239:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/96\">",
"      Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis 2012; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/97\">",
"      Pellecchia MT, Valente EM, Cif L, et al. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology 2005; 64:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/98\">",
"      Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med 2003; 348:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/99\">",
"      Margolis RL, Holmes SE, Rosenblatt A, et al. Huntington's Disease-like 2 (HDL2) in North America and Japan. Ann Neurol 2004; 56:670.",
"     </a>",
"    </li>",
"    <li>",
"     Margolis RL. Huntington disease-like 2. In: GeneReviews [Internet]. file://www.ncbi.nlm.nih.gov/books/NBK1529/ (Accessed on March 17,2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/101\">",
"      Margolis RL, O'Hearn E, Rosenblatt A, et al. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann Neurol 2001; 50:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/102\">",
"      Rudnicki DD, Holmes SE, Lin MW, et al. Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol 2007; 61:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/103\">",
"      Santos C, Wanderley H, Vedolin L, et al. Huntington disease-like 2: the first patient with apparent European ancestry. Clin Genet 2008; 73:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/104\">",
"      Walker RH, Jankovic J, O'Hearn E, Margolis RL. Phenotypic features of Huntington's disease-like 2. Mov Disord 2003; 18:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/105\">",
"      Walker RH, Rasmussen A, Rudnicki D, et al. Huntington's disease--like 2 can present as chorea-acanthocytosis. Neurology 2003; 61:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33833/abstract/106\">",
"      Walker RH, Morgello S, Davidoff-Feldman B, et al. Autosomal dominant chorea-acanthocytosis with polyglutamine-containing neuronal inclusions. Neurology 2002; 58:1031.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14122 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6001DE224-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33833=[""].join("\n");
var outline_f33_2_33833=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H88328894\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1982873\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1983214\">",
"      ABETALIPOPROTEINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1982880\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88328206\">",
"      Laboratory and test findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88328191\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1982894\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1982943\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1982957\">",
"      CHOREA-ACANTHOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1982964\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88328413\">",
"      Laboratory and test findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1983013\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1983027\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1983076\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1983242\">",
"      MCLEOD SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1983083\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H88328858\">",
"      Laboratory and test findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1983132\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1983146\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1983188\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4519453\">",
"      PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4519438\">",
"      HUNTINGTON DISEASE-LIKE 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H88328894\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/14122\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/14122|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/26/14760\" title=\"picture 1\">",
"      Acanthocytes or spur cells",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/36/15943?source=related_link\">",
"      Bradykinetic movement disorders in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/33/10777?source=related_link\">",
"      Causes of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/36/10826?source=related_link\">",
"      Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/16/1290?source=related_link\">",
"      Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13018?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15432?source=related_link\">",
"      Friedreich ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29832?source=related_link\">",
"      Huntington disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39385?source=related_link\">",
"      Huntington disease: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5210?source=related_link\">",
"      Overview of the causes of chronic diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/12/28871?source=related_link\">",
"      Overview of vitamin E",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/63/32762?source=related_link\">",
"      Pharmacologic treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/27/19896?source=related_link\">",
"      Retinitis pigmentosa: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9305?source=related_link\">",
"      Spiculated cells (echinocytes and acanthocytes) and target cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/22/32105?source=related_link\">",
"      Surgical treatment of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/35/29242?source=related_link\">",
"      The spinocerebellar ataxias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/52/12105?source=related_link\">",
"      Treatment of dystonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_2_33834="Overview of complications occurring in the post-anesthesia care unit";
var content_f33_2_33834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of complications occurring in the post-anesthesia care unit",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33834/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33834/contributors\">",
"     David B Glick, MD, MBA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33834/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33834/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/2/33834/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/2/33834/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/2/33834/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1324456773\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timely recognition and management of issues that arise in the immediate postoperative period saves lives, time, and money. The likelihood that a specific complication will arise for a given patient is determined by the nature of the procedure, the anesthetic techniques used, and the patient's preoperative comorbidities. The risk of some complications can be reduced with appropriate preoperative assessment and medical optimization.",
"   </p>",
"   <p>",
"    The most common postoperative problems encountered in the post-anesthesia care unit (PACU) will be reviewed here. Preoperative evaluation and preventive strategies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=see_link\">",
"     \"Management of cardiac risk for noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1271068\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complication in the post-anesthesia care unit (PACU) is postoperative nausea and vomiting (PONV), with incidences reported between 10 and 30 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A retrospective review involving 18,473 patients found an overall incidence of PACU complications of 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/1\">",
"     1",
"    </a>",
"    ]. After PONV, the most common complications were upper airway problems (6.9 percent), hypotension (2.7 percent), dysrhythmias (1.4 percent), hypertension (1.1 percent), altered mental status (0.6 percent), and suspected or major cardiac events (0.6 percent).",
"   </p>",
"   <p>",
"    The complications of awareness during anesthesia and visual loss may first present in the PACU and, although rare, these have received considerable attention in both the medical and lay press. (See",
"    <a class=\"local\" href=\"#H154733740\">",
"     'Intraoperative awareness'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H154733726\">",
"     'Visual disturbance'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1324456782\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE NAUSEA/VOMITING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative nausea and vomiting (PONV) is the most common complication in the immediate postoperative period. Control of nausea or vomiting is a necessary criterion for discharge from the post-anesthesia care unit (PACU), regardless of whether the patient is going home or being admitted.",
"   </p>",
"   <p>",
"    Late PONV, which is PONV after discharge from the PACU, is associated with the diminishing effect of perioperative antiemetic dosing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dizziness from turning in hospital hallways during transport on a wheeled stretcher or the movement of a car during the ride home from the hospital following outpatient surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PONV affects surgery in the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PONV is reported to be the worst patient fear going into surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/4\">",
"       4",
"      </a>",
"      ]. Fear of PONV is worse than fear of potential surgical pain.",
"     </li>",
"     <li>",
"      Patient satisfaction following surgery is significantly decreased when PONV occurs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A patient with severe PONV may require unplanned admission to the hospital [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with PONV remain in the PACU longer than expected. Delays in discharging patients from the PACU, in turn, delay the ability to turnover patients in the operating room [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The development of late PONV during patient transport causes unnecessary patient discomfort.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194729369\">",
"    <span class=\"h2\">",
"     Risk factors for PONV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of PONV is increased following anesthesia with volatile anesthetics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    , and opioids; in neurological, head or neck, abdominal, and possibly breast surgery, and in surgery of longer duration; and in patients with female gender, non-smokers, and those with a prior history of PONV or motion sickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General anesthesia using volatile anesthetics and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    is associated with an increased incidence of PONV compared with other anesthetic techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Of the available choices for anesthesia, regional anesthetic techniques have the lowest risk. If general anesthesia is needed in a patient at high risk for PONV, total intravenous anesthesia (TIVA) can be used instead of volatile anesthetics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type of surgery appears to be associated with risk of PONV, but evidence for the effect of type of surgery is conflicting as reference groups differ widely and funnel plots suggest significant publication bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a systematic review of observational studies and randomized trials, laparoscopy, laparotomy, breast, strabismus, plastic, maxillofacial, gynecological, abdominal, neurologic, ophthalmologic, and urologic surgeries were all either associated with or were an independent risk factor for PONV [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a retrospective review of 18,109 oncology surgeries, patients undergoing neurological, head or neck, and abdominal procedures were administered first dose or rescue PACU antiemetics more often than the control group of patients undergoing musculoskeletal and superficial surgeries [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/6\">",
"       6",
"      </a>",
"      ]. Use of PACU antiemetics was similar for patients having breast or axillary surgery and controls. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patient factors that are associated with higher rates of PONV include female gender, younger age, a history of motion sickness, absence of a history of smoking, and prior PONV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/7\">",
"     7",
"    </a>",
"    ]. The simplified Apfel scale, and others like it, attempts to predict the likelihood that a patient will suffer from PONV independent of anesthetic or procedure-related risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/9,12-18\">",
"     9,12-18",
"    </a>",
"    ]. An increasing number of points (from 0 to 4) correlates with an increased probability of developing postoperative nausea or vomiting. As an example, each of the following characteristics scores a point on the Apfel scale: female sex, history of motion sickness, nonsmoker, planned postoperative opioid treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/15,19\">",
"     15,19",
"    </a>",
"    ]. A patient scoring four points has a 78 percent chance of PONV (",
"    <a class=\"graphic graphic_figure graphicRef86808 \" href=\"mobipreview.htm?8/18/8494\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194727297\">",
"    <span class=\"h2\">",
"     Pharmacologic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preemptive pharmacologic treatment (prophylaxis) before the development of PONV significantly reduces the incidence of PONV. Treatment of PONV in a patient who was not given prophylaxis or who developed PONV in spite of prophylaxis is termed rescue therapy.",
"   </p>",
"   <p>",
"    Drugs classes that are available for prophylaxis or rescue therapy PONV include serotonin-receptor antagonists, corticosteroids, anticholinergic agents, and neurokinin-receptor antagonists. The neurokinin-receptor antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    ) are the latest class of antiemetic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194727319\">",
"    <span class=\"h3\">",
"     Serotonin-receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective serotonin-receptor (5-HT3) antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    , ramosetron, tropisetron) can be used prophylactically or for rescue treatment of PONV. The serotonin-receptor antagonists are the most commonly used pharmacologic agents for PONV because they do not have sedative side effects and intravenous preparations are available. Two serotonin-receptor antagonists are available as generic drugs in the United States (ondansetron and granisetron), which has decreased the cost associated with their use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link&amp;anchor=H8#H8\">",
"     \"Characteristics of antiemetic drugs\", section on 'Serotonin receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serotonin receptor-antagonists suppress the initiation of nausea and vomiting by blocking serotonin peripherally at vagal afferents and centrally in the chemoreceptor trigger zone.",
"   </p>",
"   <p>",
"    Electrocardiogram (ECG) interval changes are a class effect of the first-generation 5-HT3 antagonists, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    . They appear to be most prominent one to two hours after a dose of these agents, are mostly small and clinically insignificant, and return to baseline within 24 hours. However, potentially fatal cardiac arrhythmias, including torsade de pointes, have been reported in association with QTc prolongation. In 2011 the United States Food and Drug Administration (FDA) issued a warning concerning QTc prolongation due to ondansetron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Revised ondansetron labeling includes a recommendation to avoid use in patients with congenital long-QT syndrome and to use ECG monitoring in certain patients, including those with hypokalemia or hypomagnesemia, heart failure, bradyarrhythmias, and in patients taking other medications that increase the risk of QTc prolongation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link&amp;anchor=H8#H8\">",
"     \"Characteristics of antiemetic drugs\", section on 'Serotonin receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serotonin-receptor antagonists are most effective when given at the end of the surgical procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/22\">",
"     22",
"    </a>",
"    ]. The intravenous dosing for PONV prophylaxis is:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       Ondansetron",
"      </a>",
"      4 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"       Dolasetron",
"      </a>",
"      12.5 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"       Granisetron",
"      </a>",
"      0.35 to 1.5 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"       Palonosetron",
"      </a>",
"      0.075 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The intravenous dose needed to treat established PONV (rescue dose) in patients who have not received a serotonin antagonist for prophylaxis is lower than the dose needed for prophylaxis. However, patients who have failed one class of drug should be treated with another class as the rescue antiemetic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Starting doses are generally as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"       Ondansetron",
"      </a>",
"      1 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"       Dolasetron",
"      </a>",
"      12.5 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"       Granisetron",
"      </a>",
"      0.1 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/18/34085?source=see_link\">",
"       Palonosetron",
"      </a>",
"      0.075 mg",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194727326\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) can also be used prophylactically to control PONV. In meta-analyses of placebo-controlled randomized trials, prophylactic dexamethasone reduced the incidence of postoperative nausea and vomiting by approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]. This effect was observed across a variety of surgical procedures and with general and neuraxial opioid anesthesia. The standard prophylactic dose of dexamethasone is 4 mg intravenously, at the induction of anesthesia. In a meta-analysis of 60 randomized trials, a 4 to 5 mg dose had similar clinical effects to an 8 to 10 mg dose of dexamethasone in preventing postoperative nausea and vomiting, when given either as a single drug, or in conjunction with other anti-emetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There was no increase in side-effects or complications when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    was used.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     Dexamethasone",
"    </a>",
"    is generally not useful for rescue therapy once PONV has developed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link&amp;anchor=H10#H10\">",
"     \"Characteristics of antiemetic drugs\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism by which corticosteroids prevent PONV prophylaxis is uncertain; however, it is likely these agents exert their effects by reducing surgery-induced inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194727333\">",
"    <span class=\"h3\">",
"     Anticholinergics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticholinergic agents, and, specifically, transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    , are more commonly used for prophylaxis of PONV than for rescue therapy due to a slow onset of action. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link&amp;anchor=H2#H2\">",
"     \"Characteristics of antiemetic drugs\", section on 'Anticholinergic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The exact mechanism by which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    prevents PONV is also uncertain, but it may block cholinergic transmission from the vestibular nuclei to higher centers in the central nervous system, and from the reticular formation to the vomiting center.",
"   </p>",
"   <p>",
"    Common side effects of transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    include sedation, visual disturbances, dry mouth, and dizziness. The drug should be avoided in patients with narrow angle glaucoma.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     Scopolamine",
"    </a>",
"    is applied as a patch (1.5 mg, to release 1 mg over three days) behind the ear four or more hours prior to the end of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. The patch can also be applied the night before surgery. It is standard practice to apply the patch no sooner than one hour before cesarean section to reduce the exposure of the newborn to the drug. The time to onset of action is slow (two to four hours) but the effect is prolonged, which may be beneficial in preventing late PONV. Scopolamine patch is typically removed 24 hours after the end of surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194727340\">",
"    <span class=\"h3\">",
"     Neurokinin-receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurokinin is a naturally occurring pro-emetic substance.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     Aprepitant",
"    </a>",
"    , which is a neurokinin-receptor antagonist, is effective as a prophylactic agent for PONV. Because aprepitant is available only in oral form and has a long onset of action, it is not effective for rescue therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=see_link&amp;anchor=H9#H9\">",
"     \"Characteristics of antiemetic drugs\", section on 'Neurokinin receptor antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    , the long duration of action makes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    a good choice for preventing late PONV. However, because of cost considerations, it is typically reserved for patients in whom PONV would cause serious clinical problems. Aprepitant 40 mg orally may be administered within three hours before induction of anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194727600\">",
"    <span class=\"h3\">",
"     Preemptive analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preemptive analgesia which minimizes the need for narcotic agents to manage postoperative pain decreases the incidence of PONV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of postoperative pain\", section on 'Preemptive analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1898562439\">",
"    <span class=\"h2\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials support the use of alternative therapies such as the more liberal use of intravenous fluids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/33,34\">",
"     33,34",
"    </a>",
"    ] and",
"    <span class=\"nowrap\">",
"     acupuncture/stimulation",
"    </span>",
"    therapy to reduce the incidence of PONV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/35-38\">",
"     35-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Higher FiO",
"    <sub>",
"     2",
"    </sub>",
"    (70 to 80 percent) has also been used as a supplemental therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/39\">",
"     39",
"    </a>",
"    ]. However, a systematic review that identified 10 trials comparing 80 percent oxygen with 30 to 40 percent oxygen found no significant differences in the early, late, or overall incidence in PONV between the groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194772529\">",
"    <span class=\"h2\">",
"     Efficacy of pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review evaluating 60 medications identified nine (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    , ramosetron, tropisetron,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/54/32612?source=see_link\">",
"     cyclizine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    ) that each significantly reduced the incidence of PONV compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/41\">",
"     41",
"    </a>",
"    ]. Any one of these agents decreased the risk of PONV 20 to 40 percent compared with placebo (",
"    <a class=\"graphic graphic_table graphicRef65891 \" href=\"mobipreview.htm?29/41/30364\">",
"     table 1",
"    </a>",
"    ). The use of more than one antiemetic agent confers additional benefit. The IMPACT study found that the effect of a given drug is independent of whether a drug is given alone or with one or two other drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/2\">",
"     2",
"    </a>",
"    ]. As an example, if one drug has a relative risk of 0.60 for PONV and another of 0.70, then, when administered together, the relative risk is 0.60 X 0.70 = 0.42.",
"   </p>",
"   <p>",
"    In the systematic review, trials comparing serotonin antagonists to other agents appeared to favor serotonin antagonists; however, the comparison studies were of poor methodological quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/41\">",
"     41",
"    </a>",
"    ]. Similarly, no conclusions were drawn regarding comparisons of individual serotonin receptor antagonists (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    , ramosetron, tropisetron).",
"   </p>",
"   <p>",
"    A separate systematic review and meta-analysis identified 25 trials using transdermal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    for prophylaxis and found a significantly reduced risk of PONV (relative risk 0.73, 95% CI 0.60-0.88) compared with placebo, similar to other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/42\">",
"     42",
"    </a>",
"    ]. Combination therapy using a scopolamine patch plus a serotonin antagonist was more effective than using a scopolamine patch alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have found that neurokinin-receptor antagonists also reduce the risk of PONV compared with placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Trials are underway evaluating differing dosing regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/44,46-48\">",
"     44,46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    found no significant differences for the primary endpoint (no vomiting and no rescue therapy) between aprepitant (40 or 125 mg) compared with ondansetron, but noted that aprepitant significantly increased the incidence of no vomiting (90 or 95 versus 74 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/49\">",
"     49",
"    </a>",
"    ]. The authors noted, however, that ondansetron was administered at the time of induction and that it may have been more effective if administered at the end of surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1898562632\">",
"    <span class=\"h2\">",
"     Approach to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of PONV is ideal and can be accomplished by choosing certain anesthetic techniques together with pharmacologic prophylaxis. Prior to surgery, the patient&rsquo;s risk for PONV should be assessed (",
"    <a class=\"graphic graphic_figure graphicRef86808 \" href=\"mobipreview.htm?8/18/8494\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H194729369\">",
"     'Risk factors for PONV'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1898562639\">",
"    <span class=\"h3\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following for pharmacologic prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk for PONV (no risk factors) - In general, patients with low risk for PONV do",
"      <strong>",
"       not",
"      </strong>",
"      require PONV prophylaxis. However, if the procedure is associated with the potential for significant complications if the patient develops PONV (eg, fundoplication, ventral hernia repair), or if increased intracranial pressure postoperatively would be detrimental, then prophylaxis is appropriate.",
"     </li>",
"     <li>",
"      Moderate risk for PONV (1 risk factor) - Patients at a moderate risk for PONV should receive a single prophylactic agent. Transdermal",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/28/33222?source=see_link\">",
"       aprepitant",
"      </a>",
"      are appropriate since each of these agents have a long duration of action which may also minimize late PONV.",
"     </li>",
"     <li>",
"      High risk for PONV (&gt;1 risk factor) - In patients who are at high risk for PONV, most clinicians use multiple (two or three) pharmacologic agents for prophylaxis. In addition, inhalational anesthetics should be avoided (if possible) and postoperative opioids minimized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1898562646\">",
"    <span class=\"h3\">",
"     Rescue therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rescue therapy is not as effective as prophylaxis and is frequently needed in patients who were not given prophylaxis or developed PONV despite receiving prophylactic medication.",
"   </p>",
"   <p>",
"    When PONV develops in spite of pharmacologic prophylaxis, a different class of antiemetics is chosen for rescue therapy from the class used for prophylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/23,50\">",
"     23,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serotonin-receptor antagonists are the most commonly used agents for rescue therapy. (See",
"    <a class=\"local\" href=\"#H194727319\">",
"     'Serotonin-receptor antagonists'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H194772529\">",
"     'Efficacy of pharmacotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1275230\">",
"    <span class=\"h1\">",
"     RESPIRATORY COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory problems are the second most common complication in the postoperative period. (See",
"    <a class=\"local\" href=\"#H1271068\">",
"     'Incidence'",
"    </a>",
"    above.) Patients with significant comorbidities, particularly neuromuscular, pulmonary, or cardiac dysfunction, are at a higher risk for respiratory compromise, but any patient can develop hypoxemia following surgery. Hypoxemia (low PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) is due to hypoventilation (low PAO",
"    <sub>",
"     2",
"    </sub>",
"    ) or compromised alveolar oxygen exchange which increases the alveolar to arterial (A-a) oxygen gradient.",
"   </p>",
"   <p>",
"    In the immediate postoperative period, the most common causes of hypoventilation include airway obstruction, the effects of anesthetics, analgesics (eg, opioids), sedatives, residual neuromuscular blockade, and poorly controlled incisional pain impairing respiration. (See",
"    <a class=\"local\" href=\"#H154734943\">",
"     'Airway obstruction'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H154735372\">",
"     'Residual effects of anesthesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Impaired oxygen exchange in the postoperative period can occur as a result of intrapulmonary shunting, pulmonary edema, and pulmonary embolus. (See",
"    <a class=\"local\" href=\"#H154735004\">",
"     'Compromised oxygen exchange'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154734943\">",
"    <span class=\"h2\">",
"     Airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of airway obstruction in the post-anesthesia care unit (PACU) is pharyngeal laxity due to weakness of the pharyngeal muscles. Other causes include laryngospasm, airway edema, hematoma, or a foreign body (eg, dentures). Postoperative stridor is an emergency that requires immediate evaluation by a healthcare provider experienced in advanced airway techniques. A surgical airway may be required in some cases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36068?source=see_link\">",
"     \"Advanced emergency airway management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11945?source=see_link\">",
"     \"Overview of tracheostomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following the relief of acute airway obstruction, pulmonary edema termed \"negative pressure pulmonary edema,\" may result. The incidence is about 0.1 percent of all anesthesia cases and it occurs more often in young adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of the management of postoperative pulmonary complications\", section on 'Pulmonary edema'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498363751\">",
"    <span class=\"h3\">",
"     Pharyngeal muscular weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of pharyngeal motor tone leading to muscular laxity is due to residual neuromuscular blockade, residual anesthetic effect, or opioids. Preoperative medical conditions such as obstructive sleep apnea can also predispose to airway obstruction in the PACU.",
"   </p>",
"   <p>",
"    The diaphragm recovers more quickly from the effects of muscle relaxants than the pharyngeal musculature. Residual paralysis of pharyngeal muscles causes the base of the tongue and the tissues of the posterior oropharynx to move toward each other, obstructing the supraglottic inlet. As the patient attempts to draw in air, negative pressure generated in the thorax brings the pharyngeal tissues even closer together, further obstructing the airway. Clinically, the absence of airflow into the trachea is manifested as retraction at the sternal notch and paradoxical motion of the abdominal musculature.",
"   </p>",
"   <p>",
"    The treatment of airway obstruction due to decreased pharyngeal muscle tone is the classic jaw thrust maneuver that brings forward the mandible and the base of the tongue, which is attached to it, thus opening the inlet to the posterior oropharynx. Continuous positive airway pressure (CPAP) via a facemask can also be given to hold the airway open until pharyngeal muscle tone returns to normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=see_link&amp;anchor=H4#H4\">",
"     \"Basic airway management in adults\", section on 'Airway obstruction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If muscular weakness persists, the residual effects of muscle relaxants, sedatives, or opioids should be reversed. (See",
"    <a class=\"local\" href=\"#H154735372\">",
"     'Residual effects of anesthesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498363758\">",
"    <span class=\"h3\">",
"     Laryngospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngospasm as a cause of airway obstruction is more common in pediatric patients, but it can also occur in adults. Laryngospasm can occur abruptly following extubation in the patient who is no longer deeply anesthetized and not indifferent to laryngeal stimulation, but not awake enough to counteract the laryngeal reflex that results from vocal cord irritation (eg, tube removal, aspirate blood). Laryngospasm can also occur upon cessation of positive pressure ventilation via face mask, presumably due to sudden airway collapse.",
"   </p>",
"   <p>",
"    The treatment of laryngospasm is positive pressure ventilation. If bag-mask ventilation is not successful, a small dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV) can be given to relax the cords.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194737525\">",
"    <span class=\"h3\">",
"     Vocal cord paralysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vocal cord paralysis due to bilateral recurrent laryngeal nerve injury can present in much the same way as laryngospasm and will not be apparent until the patient is extubated. Passage of air into the lungs is not possible.",
"   </p>",
"   <p>",
"    The vocal cords will be seen to be in apposition at the midline with the laryngoscope. Attempted intubation in this setting is traumatic and often unsuccessful. Emergent tracheostomy is the appropriate initial intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498363765\">",
"    <span class=\"h3\">",
"     Airway edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The airway can become edematous due to direct tissue trauma from multiple intubation attempts or surgical manipulation, or because of decreased venous drainage resulting from prolonged head-down or prone positioning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=see_link&amp;anchor=H8#H8\">",
"     \"Endotracheal tube management and complications\", section on 'Laryngeal injury'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If airway edema is suspected, an endotracheal tube leak test can be performed once the patient is breathing spontaneously. The leak test is accomplished by deflating the cuff on the endotracheal tube and then covering the open end of the endotracheal tube to determine if the patient is capable of breathing around the tube. Alternatively, with the cuff deflated, the measured inspired volume can be compared with the exhaled volume on the ventilator. Significant airway edema is suggested if there is not a marked loss of tidal volume.",
"   </p>",
"   <p>",
"    The endotracheal tube should remain in place if airway edema compromises the patency of the airway. The head is elevated to facilitate venous drainage. Steroids can also be given to decrease swelling associated with airway inflammation. Once an air leak around the endotracheal tube is apparent, extubation is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498363772\">",
"    <span class=\"h3\">",
"     Postoperative cervical hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following surgery in the neck, postoperative bleeding from vascular structures can lead to a cervical hematoma. As blood accumulates, it can compress the membranous posterior wall of the trachea and compromise the tracheal lumen. The lumen is often narrowed to less than 5 mm before the patient becomes clinically symptomatic.",
"   </p>",
"   <p>",
"    Direct laryngoscopy will reveal only a dark mass along the posterior wall of the trachea. Attempts to intubate will be traumatic and unsuccessful. To secure a safe airway, the operative skin incision should be re-opened and the hematoma evacuated before attempting re-intubation.",
"   </p>",
"   <p>",
"    Ideally, the patient should be taken emergently to the operating room, the neck prepped and draped, and the sutures or staples removed. The hematoma can then be evacuated from the wound, sponges placed into the wound and pressure applied to control bleeding while the patient is intubated. Once the airway is secured, surgical exploration can be continued to identify and control the source of bleeding, irrigate the wound, and re-close the incision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498363779\">",
"    <span class=\"h3\">",
"     Foreign bodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dentures, teeth, surgical packs, or instruments can also obstruct the airway. Direct laryngoscopy or rigid bronchoscopy may be necessary to extract the obstructing object. Digital sweep through the mouth risks pushing the foreign body deeper into the airway",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    converting a partial obstruction to a complete obstruction, and should not be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis and management of central airway obstruction\", section on 'Foreign body extraction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154735372\">",
"    <span class=\"h2\">",
"     Residual effects of anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of a procedure, the patient&rsquo;s respiration is supported with positive pressure ventilation until the effects of the administered anesthetic agents wear off. (See",
"    <a class=\"local\" href=\"#H194750724\">",
"     'Supportive care'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One of the effects of volatile anesthetics, many intravenous",
"    <span class=\"nowrap\">",
"     sedative/hypnotic",
"    </span>",
"    agents, and opioids is a decrease in the sensitivity of the respiratory center to rises in carbon dioxide, which then diminishes the respiratory drive. Intravenous sedatives like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    have less of a suppressive effect.",
"   </p>",
"   <p>",
"    A diminished respiratory drive manifests as a reduced respiratory rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tidal volume. As an example, the tidal volume is decreased but the respiratory rate may increase with the use of volatile anesthetic agents. In contrast, the respiratory rate decreases with the use of opioids while the tidal volume remains normal. The neuromuscular blockers have a direct effect on the musculature and reduce tidal volume because of reduced diaphragmatic movement. If prolonged, pharmacologic reversal may be necessary, as guided by the patient&rsquo;s clinical condition.",
"   </p>",
"   <p>",
"    Patients with compromised renal or hepatic function are at an increased risk for persistent effects from sedatives, opioids, and neuromuscular blocking agents due to reduced drug clearance. Hypothermia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acidosis also slow enzymatic degradation of some agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"     cisatracurium",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194742550\">",
"    <span class=\"h3\">",
"     Pharmacologic reversal",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no reversal agents for the volatile gases, barbiturates, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Specific antidotes are available to reverse the effects of benzodiazepines, anticholinergics, and neuromuscular blocking agents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benzodiazepines &ndash; Oversedation caused by benzodiazepines, which are administered as a premedication before surgery, has become uncommon since",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      was replaced by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      , a shorter-acting agent. When reversal is needed, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/6/41062?source=see_link\">",
"       flumazenil",
"      </a>",
"      is given. Because flumazenil is generally shorter-acting than the sedative it is reversing, the patient must be closely monitored for evidence of returning sedation, and additional doses of flumazenil given, as necessary. In adults, the recommended initial dose is 0.2 mg given intravenously (IV) over 30 seconds. Repeated doses of 0.2 mg, to a maximum dose of 1 mg, can be given until the desired effect is achieved [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/31\">",
"       31",
"      </a>",
"      ]. In the event of re-sedation, dosing can be repeated, but no more than 3 mg of flumazenil should be given within a given hour. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11080?source=see_link&amp;anchor=H14#H14\">",
"       \"Benzodiazepine poisoning and withdrawal\", section on 'Antidote (flumazenil)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anticholinergics &ndash; The sedative effects of the central-acting anticholinergics,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      , can be antagonized with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/27/40372?source=see_link\">",
"       physostigmine",
"      </a>",
"      , but this is not usually necessary. The recommended dose of physostigmine is 0.5 to 2 mg (0.02",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV, up to a maximum of 0.5 mg per dose in pediatric patients). The drug should be given by slow intravenous push, generally over five minutes. Overly rapid infusion may result in cholinergic symptoms or seizures. The treatment of anticholinergic side effects is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=see_link&amp;anchor=H11#H11\">",
"       \"Anticholinergic poisoning\", section on 'Antidotal therapy with physostigmine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuromuscular blocking agents &ndash; It is customary to reverse neuromuscular blockade using one of the pseudocholinesterase inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/41/10901?source=see_link\">",
"       neostigmine",
"      </a>",
"      ) in most patients who received nondepolarizing neuromuscular blocking agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/46/15079?source=see_link\">",
"       vecuronium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"       rocuronium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/1/26646?source=see_link\">",
"       cisatracurium",
"      </a>",
"      ). Complete recovery from neuromuscular blockade is correlated with a train-of-four (TOF) peripheral nerve stimulation ratio of 0.9, or the ability to hold a tongue depressor between the molars. The TOF ratio is defined as the amplitude of the twitch response to a fourth nerve stimulation relative to the twitch response of the first stimulation. If the patient is reversed before these signs are apparent, the neuromuscular blocking agent will still be circulating after the reversal agent has worn off. A second dose of the reversing agent can be given, but the patient needs to be observed carefully and should be reintubated if weakness persists.",
"      <br/>",
"      <br/>",
"      In some patients, persistent paralysis may be due to the administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      or mivacurium in a patient with pseudocholinesterase deficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31288?source=see_link&amp;anchor=H6#H6\">",
"       \"Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults\", section on 'Contraindications and side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Opioids &ndash; When hypoventilation is due to narcotics, treatment is supportive with positive pressure ventilation and, if needed, reversal using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      (40 micrograms every five minutes, intravenously, until adequate reversal is achieved). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=see_link&amp;anchor=H13#H13\">",
"       \"Opioid intoxication in adults\", section on 'Management'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Reversal with naloxone is generally safe but is not without risks. Like the benzodiazepines, the half-life of the opioid being reversed may be longer than naloxone (half-life 1 to 1.5 hours), and thus, the patient must be monitored for re-sedation as the naloxone wears off. Repeat doses can be given, or, alternatively, a continuous infusion can be started. It is important to remember that, in addition to reversing the sedative and respiratory depressant effects, naloxone also reverses the analgesic effects of the narcotic, which can be extremely uncomfortable for the patient, and in patients with cardiac disease the associated sympathetic surge can lead to myocardial ischemia. Flash pulmonary edema has also been reported after large doses of naloxone in young, muscular patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154735004\">",
"    <span class=\"h2\">",
"     Compromised oxygen exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inadequate exchange of oxygen from the alveoli into the pulmonary capillaries leading to hypoxemia can be due to intrapulmonary shunting, pulmonary edema, or pulmonary embolus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intrapulmonary shunting &ndash; Lung collapse (eg, atelectasis, pneumothorax) leads to regions of the lung that are perfused but not ventilated, which can result in significant hypoxemia if a large amount of blood is shunted. Treatment for atelectasis is supportive, consisting of adequate analgesia, deep breathing and coughing, incentive spirometry or, in some cases, positive pressure ventilation to open the collapsed segment. Treatment for pneumothorax requires evacuation of the air by placement of a chest tube. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link&amp;anchor=H2#H2\">",
"       \"Placement and management of thoracostomy tubes\", section on 'Indications'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary edema &ndash; Pulmonary edema diminishes the lung's capacity to move oxygen from the alveoli into the pulmonary capillaries and can also lead to hypoxemia. In the postoperative period, patients at risk for pulmonary edema often have preexisting heart failure, but pulmonary edema can also develop in otherwise healthy patients as a sequelae of airway obstruction (negative pressure pulmonary edema), or following narcotic reversal with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      (flash pulmonary edema). Treatment of pulmonary edema is supportive. Supplemental oxygen is given and positive pressure ventilation is added, as needed. The treatment of postoperative pulmonary edema and postoperative heart failure are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=see_link&amp;anchor=H32#H32\">",
"       \"Overview of the management of postoperative pulmonary complications\", section on 'Pulmonary edema'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link\">",
"       \"Perioperative heart failure in noncardiac surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary embolus &ndash; Although uncommon in the early postoperative period, pulmonary embolus can occur due to vein thrombus, fat (eg, long bone surgery), or amniotic fluid (childbirth). A diagnosis of pulmonary embolus should be suspected in patients with suggestive clinical symptoms and signs which include chest pain, tachycardia, and hypoxemia resistant to supplemental oxygen. The diagnosis and treatment of pulmonary embolus is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=see_link\">",
"       \"Treatment of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194750724\">",
"    <span class=\"h2\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive care of respiratory complications in the PACU consists of pain control, supplemental oxygen, and positive pressure respiratory support. It is important to remember that hypoventilating patients can become hypoxic breathing room air. Pharmacologic reversal of the residual effects of anesthetic medication may be needed and is discussed separately. (See",
"    <a class=\"local\" href=\"#H194742550\">",
"     'Pharmacologic reversal'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who have incisions in the chest or upper abdomen often find it painful to breathe deeply. The best way to treat this cause of hypoventilation is to provide adequate analgesia, which will improve tidal volume. Non-sedating alternatives for pain control include non-narcotic intravenous analgesics and regional analgesia (eg, epidural catheter placement, intercostal block, transversus abdominus plane block). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Short-term positive pressure ventilation is provided using bag-mask ventilation. If a longer period of support will be required, noninvasive positive pressure ventilation (NIPPV) can be used. NIPPV uses a tightly fitting facemask to administer CPAP or a nasal mask to give bilevel positive airway pressure (BiPAP). CPAP, which delivers a steady plateau of pressure to the lungs, raises mean airway pressure, recruits collapsed alveoli, increases minute ventilation, and maintains upper airway patency. BiPAP provides a continuous level of pressure through the upper airway with all the benefits of CPAP, but it also delivers an incremental increase in pressure with inspiration. This additional level of airway support allows the respiratory muscles to rest. If noninvasive techniques are not adequate, reintubation may be required. The details and use of NIPPV are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1324456938\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular complications in the postoperative patient are related to the severity of cardiovascular comorbidities (eg, coronary artery disease, hypertension), and the nature and course (eg, blood loss) of the operation.",
"   </p>",
"   <p>",
"    Surgical patients with ischemic heart disease or a history of heart failure are less tolerant of the stress that surgery places on the heart, and these patients are more likely to present with cardiovascular complications in the post-anesthesia care unit (PACU). The surgical procedure can lead to cardiovascular complications through indirect",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    direct effects. As an example, blood loss during surgery may result in hypotension and hypoperfusion with cardiovascular injury as an indirect consequence. On the other hand, operations near the heart or mediastinum (eg, cardiac, pulmonary, or esophageal surgeries) can cause myocardial irritability and postoperative arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1324456945\">",
"    <span class=\"h2\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many etiologies for hypotension in patients managed in the PACU. The most significant of these include hypovolemia, heart failure, sepsis, drug effects, anaphylaxis, and pulmonary embolus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypovolemia &ndash; Inadequate intravascular volume can be due to inadequate fluid replacement during the course of the operation. If intraoperative blood loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ongoing blood loss is the cause of the hypovolemia, blood products are given as part of the ongoing resuscitation. It is important to remember that the postoperative hematocrit will not accurately reflect the degree of blood loss until adequate fluid resuscitation has occurred. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=see_link\">",
"       \"Maintenance and replacement fluid therapy in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"       \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myocardial",
"      <span class=\"nowrap\">",
"       ischemia/heart",
"      </span>",
"      failure &ndash; In the perioperative period, hypotension can also be due to myocardial",
"      <span class=\"nowrap\">",
"       ischemia/infarction,",
"      </span>",
"      heart failure, cardiac valvular dysfunction, and cardiac arrhythmia. (See",
"      <a class=\"local\" href=\"#H1324456987\">",
"       'Arrhythmias'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Patients with preexisting coronary artery disease and patients with drug-eluting stents whose antiplatelet therapy was prematurely withheld are at increased risk for perioperative myocardial ischemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=see_link\">",
"       \"Perioperative heart failure in noncardiac surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29975?source=see_link\">",
"       \"Perioperative myocardial infarction after noncardiac surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link&amp;anchor=H8#H8\">",
"       \"Antiplatelet therapy after coronary artery stenting\", section on 'Premature cessation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decreased vascular resistance &ndash; Hypotension related to decreased systemic vascular resistance is due to the combined effects of decreased atrial filling and reduced afterload.",
"      <br/>",
"      <br/>",
"      Iatrogenic causes of decreased vascular resistance are related to the administration of various pharmacologic agents such as the vasodilators sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"       nitroprusside",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      to treat hypertension, or the prolonged effect of long-acting anti-hypertensives (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/58/937?source=see_link\">",
"       lisinopril",
"      </a>",
"      ) taken by the patient on the morning of surgery. Epidural and spinal anesthetics also decrease peripheral vascular resistance by causing venodilation. When treating hypotension in patients with an epidural or spinal anesthetic, vasoconstricting agents are preferred over additional fluid, particularly in patients who will have trouble clearing the fluid load when vascular tone returns to normal (eg, patients with renal insufficiency, history of heart failure).",
"      <br/>",
"      <br/>",
"      Many disease states also decrease vascular resistance and can lead to postoperative hypotension. As examples, endotoxins released during surgery for intraabdominal sepsis, spinal shock due to spinal cord injury, and histamine release from mast cells during anaphylaxis can all cause profound hypotension mediated by a decrease in vascular resistance. Treatment is directed at the underlying cause (eg, antibiotics for sepsis,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      to stabilize the mast cells in anaphylaxis), and symptomatic therapy includes intravenous vasoconstrictors (eg, vasopressin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      ) and fluid resuscitation; high fluid volumes are often needed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link\">",
"       \"Evaluation and management of severe sepsis and septic shock in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=see_link\">",
"       \"Acute traumatic spinal cord injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=see_link\">",
"       \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1324456980\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop hypertension in the PACU are at a higher risk for postoperative complications (eg, unplanned intensive care unit admission) compared with patients who experience an episode of hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/53\">",
"     53",
"    </a>",
"    ]. The most common cause of hypertension in the PACU is preoperative hypertension, particularly if the patient did not take their usual anti-hypertensive agent(s) on the morning of surgery. Other frequent causes of hypertension in the PACU include inadequate pain control, hypoventilation, urinary retention, and anxiety. Less commonly, delirium, which may be a manifestation of alcohol or drug withdrawal, can also contribute. These are reviewed briefly below. The general treatment of hypertension in the perioperative period is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33046?source=see_link\">",
"     \"Perioperative management of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain is a common cause of hypertension in the PACU. Inadequately treated surgical pain leads to sympathetic discharge which increases heart rate and blood pressure. A multimodal approach to pain management is preferred. Regional anesthetic techniques are useful when narcotics need to be avoided. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link\">",
"       \"Management of postoperative pain\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=see_link\">",
"       \"Pain control in the critically ill adult patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Urinary retention is an easily remedied cause of hypertension in the PACU, particularly for older men with known voiding problems due to prostatic hypertrophy or patients with decreased bladder muscle tone due to neuraxial anesthesia. If the patient has received a large volume of intravenous fluid and has not voided, the bladder should be palpated or scanned by ultrasound to determine if catheterization of the bladder is needed. (See",
"      <a class=\"local\" href=\"#H154735179\">",
"       'Postoperative urinary retention'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Hypoventilation is initially associated with an increase in sympathetic tone leading to a rise in blood pressure. Treatment is supportive with positive pressure ventilation via bag-mask ventilation or reintubation until the patient's respiratory drive returns to normal. (See",
"      <a class=\"local\" href=\"#H1275230\">",
"       'Respiratory complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative anxiety and emergence delirium can also lead to elevated blood pressures. This problem is far more common in children. Prior to giving any sedatives, other causes of anxiety (eg, pain, respiratory insufficiency) must be identified and treated first. (See",
"      <a class=\"local\" href=\"#H154733712\">",
"       'Emergence delirium'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Drug or alcohol withdrawal can also lead to hypertension in the PACU. Alcohol withdrawal can begin as early as 24 hours after consumption of the last alcoholic beverage. Early signs of withdrawal include hypertension and tachycardia. Narcotic abusers who have not received their usual dose may require additional dosing of their narcotic to manage withdrawal symptoms. The treatment of drug and alcohol withdrawal is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/5/28758?source=see_link\">",
"       \"Opioid withdrawal in the emergency setting\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11080?source=see_link\">",
"       \"Benzodiazepine poisoning and withdrawal\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1324456987\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac arrhythmias in the postoperative period can be due to acute coronary insufficiency, hypoxia, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), anesthetics, and other pharmacologic agents. The uncoordinated cardiac contraction can lead to marked hypotension, particularly if ventricular function is already compromised such as in the patient with poor preoperative cardiac contractility. (See",
"    <a class=\"local\" href=\"#H1324456945\">",
"     'Hypotension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most common postoperative ventricular arrhythmias are isolated premature ventricular contractions (PVCs) and ventricular bigeminy. These rhythms are unlikely to degenerate into life-threatening arrhythmias and they do not routinely require intervention. On the other hand, Torsade de Pointes (",
"    <a class=\"graphic graphic_waveform graphicRef60231 \" href=\"mobipreview.htm?35/15/36083\">",
"     waveform 1",
"    </a>",
"    ) is a polymorphic ventricular tachycardia that results from prolongation of the Q-T interval in susceptible patients who become hypomagnesemic or receive certain medications (eg, class IA or III anti-arrhythmics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    ). Torsade de Pointes can cause hypotension or degenerate into ventricular fibrillation and sudden cardiac death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the acute management of tachyarrhythmias\", section on 'Torsades de pointes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial fibrillation is most likely to occur if a patient undergoes cardiac or thoracic surgery. The rate of new onset atrial fibrillation after pneumonectomy can be 50 percent or higher, and may be due to atrial irritability or the sudden cessation of chronic beta-blockade. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=see_link\">",
"     \"Overview of the acute management of tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    New onset postoperative bradyarrhythmias are due to excess administration of antihypertensive agents (eg, beta-blockers, alpha-2 agonists), excess opioid dosing, or related to high neuraxial anesthesia (suppression of cardiac accelerator fibers originating at the level of the first through fourth thoracic vertebrae [T1-T4]). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of arrhythmias in the PACU first requires identification and correction of the underlying cause of the rhythm disturbance and thus, hypoxia, hypercarbia, ischemia, and electrolyte imbalances must be addressed. Medical management of the arrhythmias is usually enough to correct the arrhythmias, but if the tachyarrhythmias cause hemodynamic instability, electrical cardioversion may be required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=see_link\">",
"     \"Overview of the acute management of tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic bradyarrhythmias that are not corrected may require temporary pacing (transvenous or transcutaneous). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=see_link\">",
"     \"Temporary cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1324457038\">",
"    <span class=\"h1\">",
"     HYPOTHERMIA OR HYPERTHERMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia and hyperthermia have negative consequences. Decreases in body temperature as little as 2&deg; Celsius can slow drug metabolism (particularly degradation of neuromuscular blocking agents), and decrease platelet function impairing hemostasis. More profound decreases in body temperature cause somnolence. In contrast, excessive increases in body temperature cause a hypermetabolic state that increases the respiratory rate and heart rate, which can exacerbate underlying medical conditions.",
"   </p>",
"   <p>",
"    Maintenance of normothermia during recovery is important enough that the Joint Commission and the Surgical Care Improvement Project encourages warming all patients to 96.8&deg; Fahrenheit (36&deg; Celsius) within 15 minutes of their arrival in the post-anesthesia care unit (PACU) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/54\">",
"     54",
"    </a>",
"    ]. Warming in the PACU is typically achieved using forced air warming devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4139928\">",
"    <span class=\"h2\">",
"     Hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of hypothermia in the PACU include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cold environment",
"     </li>",
"     <li>",
"      Administration of room temperature IV fluids",
"     </li>",
"     <li>",
"      Medication-induced vasodilatation (eg, inhalation anesthetics)",
"     </li>",
"     <li>",
"      Decreased basal metabolic rate",
"     </li>",
"     <li>",
"      Anesthetic-induced impairment of the hypothalamic thermostat",
"     </li>",
"     <li>",
"      Exposure of body cavities to room temperature air",
"     </li>",
"     <li>",
"      Ventilation with unwarmed gasses",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154733824\">",
"    <span class=\"h2\">",
"     Shivering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shivering in the postoperative period can occur with hypothermia, hyperthermia, or normothermia. Shivering causes patient discomfort and markedly increases myocardial oxygen consumption. Shivering is treated with a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    , 12.5 to 25 mg, intravenously. Alpha-2 agonists including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    (150 micrograms intravenously) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    are used as second-line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154733840\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever is defined as a core body temperature &ge;102.2&deg; Fahrenheit (39&deg; Celsius) (",
"    <a class=\"graphic graphic_table graphicRef73846 \" href=\"mobipreview.htm?34/36/35405\">",
"     table 2",
"    </a>",
"    ). The potential causes of fever in the immediate operative and postoperative period are mainly limited to: medications or blood products to which the patient was exposed during care in the operating room or in the recovery area; trauma suffered prior to surgery or as part of surgery; infections that were present prior to surgery; and rarely, malignant hyperthermia. These entities are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19178?source=see_link\">",
"     \"Postoperative fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498363842\">",
"    <span class=\"h1\">",
"     NEUROPSYCHIATRIC COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common central nervous system abnormality in the post-anesthesia care unit (PACU) is an altered state of consciousness. Postoperative patients can demonstrate excessive sedation or agitation, which, in some cases, may be alternating. (See",
"    <a class=\"local\" href=\"#H154733712\">",
"     'Emergence delirium'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H154734385\">",
"     'Somnolence'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other neurologic problems that may be encountered include visual disturbances, complications related to regional anesthesia (epidural hematoma, neurapraxia), and intraoperative recall of the events of the operation. Early identification and treatment is important to lessen the impact of these uncommon, but potentially devastating complications. Each is discussed briefly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154733712\">",
"    <span class=\"h2\">",
"     Emergence delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergence delirium, also known as emergence agitation, refers to a prolonged (hours) change in mental status characterized by a dissociated state of consciousness in which the patient is irritable, uncooperative, uncompromising, thrashing, moaning, incoherent, or crying.",
"   </p>",
"   <p>",
"    The incidence of emergence agitation in children can be as high as 30 percent and is most common in children ages two to four. Emergence agitation is likely a response to a disorienting situation. Parental presence can smooth this transition and the child usually calms in less than 15 minutes. Pediatric emergence agitation has been attributed to the increased use of the rapid onset low-solubility inhaled anesthetic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the adult population, emergence agitation is less common, with an incidence of less than 5 percent. Transient agitation occurs in a wide range of adult postsurgical patients, but the development of delirium occurs most commonly in elderly patients, especially following major orthopedic procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Emergence delirium can be a result of pain, hypoxia, hypercarbia, urinary retention, electrolyte imbalance (especially hyponatremia), and central, drug-induced anticholinergic activity. Preoperative substance abuse and poor functional status are also risk factors for postoperative delirium. Treatment should be directed first at the underlying cause. When needed, a small dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    (1 to 2 mg, intravenous in adults) can be given to help relax the patient and consequently will reduce blood pressure if elevated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28185?source=see_link&amp;anchor=H7#H7\">",
"     \"Prevention and treatment of delirium and confusional states\", section on 'Postoperative setting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154734385\">",
"    <span class=\"h2\">",
"     Somnolence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somnolence in the PACU is most often due to the persistent effects of pharmacologic agents used during surgery, typically sedatives and neuromuscular blocking agents. (See",
"    <a class=\"local\" href=\"#H154735372\">",
"     'Residual effects of anesthesia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is important to rule out other causes of somnolence, such as hypotension, hypoxia, hypercarbia, hypoglycemia, and electrolyte abnormalities, before attributing the patient&rsquo;s condition solely to a persistent anesthetic effect. A check of routine vital signs, complete blood count, blood gas analysis, and chemistry panel will differentiate most of the potential causes of postoperative somnolence. If a cerebrovascular injury is suspected, computed tomography (CT) of the head may be needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154733726\">",
"    <span class=\"h2\">",
"     Visual disturbance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of visual disturbance in the postoperative period is corneal abrasion. The patient typically complains of the sensation of a foreign body in the affected eye. The diagnosis is made by staining the cornea with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    . Topical antibiotics and use of an eye patch typically result in full recovery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34600?source=see_link\">",
"     \"Corneal abrasions and corneal foreign bodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although rare, a patient may awaken from anesthesia with visual loss. Visual complications due to ischemic optic neuropathy or retinal artery occlusion can lead to total and permanent visual loss. Patients undergoing cardiac, spinal, and head and neck operations are at the highest risk. Risk factors include prone positioning, prolonged procedure duration, and significant blood loss or need for large volume resuscitation. An ophthalmology consultation is appropriate, but there may be little to offer the patient who has suffered this complication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20442?source=see_link&amp;anchor=H12#H12\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\", section on 'Perioperative ION'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35943?source=see_link&amp;anchor=H5#H5\">",
"     \"Posterior ischemic optic neuropathy\", section on 'Perioperative PION'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154733733\">",
"    <span class=\"h2\">",
"     Epidural hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidural hematoma is an uncommon complication of neuraxial anesthesia with a reported incidence of 1 in 150,000. The risk increases in the setting of systemic anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epidural catheters are usually placed just prior to induction of anesthesia. If an epidural hematoma develops, it will not become apparent until the patient awakens in the PACU. Symptoms include back pain or back pressure, which can progress to muscle weakness, sensory loss, and urinary or bladder dysfunction. If an epidural hematoma is suspected, an emergent MRI of the spine and neurosurgical evaluation for possible decompression should be obtained, because permanent neurological injury can result in as little as six hours from the time of onset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154733740\">",
"    <span class=\"h2\">",
"     Intraoperative awareness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Awareness with recall following anesthesia refers to conscious awareness of intraoperative events and has become an important topic of discussion in the professional and lay press. As affected patients awaken from anesthesia, they may show evidence of awareness of the surgical procedure. Any patient suspected of having an awareness event should be offered psychiatric counseling. Awareness with recall following anesthesia is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=see_link\">",
"     \"Awareness with recall following general anesthesia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154735179\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE URINARY RETENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary retention is common following anesthesia. The incidence varies widely, ranging from 5 to 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/59\">",
"     59",
"    </a>",
"    ]. Postoperative urinary retention (POUR), in the absence of urologic pathology, is usually transient but on occasion can be prolonged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194770753\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for POUR are patient-specific, procedure-specific, and anesthetic-specific.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient &ndash; Advanced age, male gender, pre-existing neurologic disease (eg, cerebral palsy, neuropathy, multiple sclerosis)",
"     </li>",
"     <li>",
"      Procedure &ndash; Anorectal surgery, joint arthroplasty, hernia repair",
"     </li>",
"     <li>",
"      Anesthesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Medications (anticholinergic agents, beta-blockers, sympathomimetics)",
"     </li>",
"     <li>",
"      Prolonged duration of anesthesia",
"     </li>",
"     <li>",
"      Excessive fluid administration",
"     </li>",
"     <li>",
"      Mode of anesthesia; neuraxial anesthesia is more likely to cause POUR compared with general anesthesia (inhaled or intravenous)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194770760\">",
"    <span class=\"h2\">",
"     Evaluation and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with POUR may or may not complain of bladder fullness or lower abdominal discomfort and physical examination is not sufficiently sensitive to detect bladder volumes before the development of overdistention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/60\">",
"     60",
"    </a>",
"    ]. Thus, the bladder is assessed directly. Bladder volume is measured by draining the bladder, which requires catheterization, or by using ultrasound. We prefer to use bladder ultrasound because ultrasound is noninvasive and urine volumes measured by ultrasound have shown a good correlation to volumes measured by bladder catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with any of the risk factors who are unable to void four hours after surgery should have a bladder ultrasound performed. Patients with more than 600 cc of urine should undergo one-time catheterization, after which ambulatory patients may be discharged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/2/33834/abstract/59\">",
"     59",
"    </a>",
"    ]. Ambulatory patients with less than 600 cc of urine in their bladder and patients without risk factors for POUR can be discharged without voiding. Patients who have not spontaneously voided prior to discharge are instructed to seek medical assistance if they have not spontaneously voided within eight hours of discharge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H154733616\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative complications are estimated to occur in about 25 percent of patients undergoing anesthesia. Complications may require additional treatment and may delay discharge from the post-anesthesia care unit (PACU). (See",
"      <a class=\"local\" href=\"#H1324456773\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common PACU complication is postoperative nausea or vomiting (PONV). The incidence following anesthesia ranges between 10 and 30 percent. Risk factors associated with higher rates of PONV include female gender, a history of motion sickness, absence of a history of smoking, prior PONV, and type of surgery, including neurological, head or neck, abdominal, and possibly breast surgery. (See",
"      <a class=\"local\" href=\"#H1324456782\">",
"       'Postoperative nausea/vomiting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to surgery, the patient should be assessed for their risk for PONV. We administer pharmacologic prophylaxis to patients with &ge;1 risk factor for PONV. For patients with a single risk factor for PONV, a single agent is adequate, whereas patients with &gt;1 risk factor generally require multiple agents. Prophylaxis is not necessary for patients who do not have risk factors. (See",
"      <a class=\"local\" href=\"#H194729369\">",
"       'Risk factors for PONV'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1898562632\">",
"       'Approach to therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When PONV develops in spite of pharmacologic prophylaxis, a different class of anti-emetics is chosen for rescue therapy from the class used for prophylaxis. (See",
"      <a class=\"local\" href=\"#H1898562646\">",
"       'Rescue therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory problems are the second most common complication arising in the PACU. Patients with significant comorbidities, particularly cardiac, neuromuscular, or pulmonary dysfunction are at a higher risk for hypoxemia due to hypoventilation or impaired oxygen exchange. In postoperative patients, hypoventilation can be due to airway obstruction, poorly controlled incisional pain, and the residual effects of anesthetics, analgesics (eg, opioids), sedatives, or neuromuscular blocking agents. Impaired oxygen exchange is most commonly due to atelectasis from pulmonary splinting, but other causes for impaired oxygen exchange include pulmonary edema, or, more rarely, pulmonary embolus. (See",
"      <a class=\"local\" href=\"#H1275230\">",
"       'Respiratory complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiovascular complications in the postoperative patient are closely correlated to pre-existing cardiovascular disease. Hypotension can be due to hypovolemia, heart failure, sepsis, drugs, cardiac arrhythmia, anaphylaxis, and pulmonary embolus. Postoperative hypertension is most commonly related to pre-existing hypertension. Inadequately controlled pain is another common cause of hypertension. Other causes include urinary retention, hypoventilation, and drug or alcohol withdrawal. Cardiac arrhythmias (tachycardia, bradycardia) can be due to cardiac ischemia, hypoxia, electrolyte abnormalities (eg, hypokalemia, hypomagnesemia), anesthetics, and other pharmacologic agents. (See",
"      <a class=\"local\" href=\"#H1324456938\">",
"       'Cardiovascular complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disturbances in thermoregulation are common, including hypothermia and hyperthermia. Shivering can occur in hypothermic, hyperthermic, or normothermic patients. Within 15 minutes of arrival in the PACU, all patients should be warmed to 96.8&deg;F (36&deg;C). Postoperative hypothermia is most often due to anesthetic induced vasodilation and impaired thermoregulation in conjunction with the cold operative environment. The potential causes of fever in the immediate operative and postoperative period are mainly limited to: medications or blood products to which the patient was exposed in the perioperative period; trauma suffered prior to surgery or as part of surgery; infections that were present prior to surgery; and rarely, malignant hyperthermia. (See",
"      <a class=\"local\" href=\"#H1324457038\">",
"       'Hypothermia or hyperthermia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common central nervous system complication in the PACU is an altered state of consciousness (delirium, agitation, somnolence). Uncommon problems include visual disturbances, complications related to regional anesthesia (epidural hematoma, neurapraxia), and recall of intraoperative events. Early identification and treatment of these uncommon problems is important to lessen the impact of these potentially devastating complications. (See",
"      <a class=\"local\" href=\"#H498363842\">",
"       'Neuropsychiatric complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary retention is common following anesthesia. The incidence varies widely, ranging from 5 to 70 percent depending upon patient, procedure, and anesthesia-specific factors. Patients with more than one risk factor for urinary retention should undergo assessment of urinary volume to determine if one-time catheterization is needed prior to discharge. All patients who have not spontaneously voided prior to discharge should seek medical attention if they have not spontaneously voided within eight hours of discharge. (See",
"      <a class=\"local\" href=\"#H154735179\">",
"       'Postoperative urinary retention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/1\">",
"      Hines R, Barash PG, Watrous G, O'Connor T. Complications occurring in the postanesthesia care unit: a survey. Anesth Analg 1992; 74:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/2\">",
"      Apfel CC, Korttila K, Abdalla M, et al. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004; 350:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/3\">",
"      Wu CL, Berenholtz SM, Pronovost PJ, Fleisher LA. Systematic review and analysis of postdischarge symptoms after outpatient surgery. Anesthesiology 2002; 96:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/4\">",
"      Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg 1999; 89:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/5\">",
"      Gold BS, Kitz DS, Lecky JH, Neuhaus JM. Unanticipated admission to the hospital following ambulatory surgery. JAMA 1989; 262:3008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/6\">",
"      Ruiz JR, Kee SS, Frenzel JC, et al. The effect of an anatomically classified procedure on antiemetic administration in the postanesthesia care unit. Anesth Analg 2010; 110:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/7\">",
"      Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology 1999; 91:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/8\">",
"      Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 2006; 102:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/9\">",
"      Koivuranta M, L&auml;&auml;r&auml; E, Sn&aring;re L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia 1997; 52:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/10\">",
"      Fern&aacute;ndez-Guisasola J, G&oacute;mez-Arnau JI, Cabrera Y, del Valle SG. Association between nitrous oxide and the incidence of postoperative nausea and vomiting in adults: a systematic review and meta-analysis. Anaesthesia 2010; 65:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/11\">",
"      Apfel CC, Heidrich FM, Jukar-Rao S, et al. Evidence-based analysis of risk factors for postoperative nausea and vomiting. Br J Anaesth 2012; 109:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/12\">",
"      Gan TJ, Meyer TA, Apfel CC, et al. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg 2007; 105:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/13\">",
"      Apfel CC, Kranke P, Eberhart LH. Comparison of surgical site and patient's history with a simplified risk score for the prediction of postoperative nausea and vomiting. Anaesthesia 2004; 59:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/14\">",
"      Stadler M, Bardiau F, Seidel L, et al. Difference in risk factors for postoperative nausea and vomiting. Anesthesiology 2003; 98:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/15\">",
"      Apfel CC, L&auml;&auml;r&auml; E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology 1999; 91:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/16\">",
"      van den Bosch JE, Kalkman CJ, Vergouwe Y, et al. Assessing the applicability of scoring systems for predicting postoperative nausea and vomiting. Anaesthesia 2005; 60:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/17\">",
"      Apfel CC, Kranke P, Eberhart LH, et al. Comparison of predictive models for postoperative nausea and vomiting. Br J Anaesth 2002; 88:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/18\">",
"      Eberhart LH, H&ouml;gel J, Seeling W, et al. Evaluation of three risk scores to predict postoperative nausea and vomiting. Acta Anaesthesiol Scand 2000; 44:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/19\">",
"      Apfel CC, Greim CA, Haubitz I, et al. A risk score to predict the probability of postoperative vomiting in adults. Acta Anaesthesiol Scand 1998; 42:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/20\">",
"      Charbit B, Alvarez JC, Dasque E, et al. Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology 2008; 109:206.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/ucm271913.htm (Accessed on September 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/22\">",
"      Tang J, Wang B, White PF, et al. The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting. Anesth Analg 1998; 86:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/23\">",
"      Habib AS, Reuveni J, Taguchi A, et al. A comparison of ondansetron with promethazine for treating postoperative nausea and vomiting in patients who received prophylaxis with ondansetron: a retrospective database analysis. Anesth Analg 2007; 104:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/24\">",
"      Pham A, Liu G. Dexamethasone for antiemesis in laparoscopic gynecologic surgery: a systematic review and meta-analysis. Obstet Gynecol 2012; 120:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/25\">",
"      Diakos EA, Gallos ID, El-Shunnar S, et al. Dexamethasone reduces pain, vomiting and overall complications following tonsillectomy in adults: a systematic review and meta-analysis of randomised controlled trials. Clin Otolaryngol 2011; 36:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/26\">",
"      Chen CC, Siddiqui FJ, Chen TL, et al. Dexamethasone for prevention of postoperative nausea and vomiting in patients undergoing thyroidectomy: meta-analysis of randomized controlled trials. World J Surg 2012; 36:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/27\">",
"      Allen TK, Jones CA, Habib AS. Dexamethasone for the prophylaxis of postoperative nausea and vomiting associated with neuraxial morphine administration: a systematic review and meta-analysis. Anesth Analg 2012; 114:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/28\">",
"      De Oliveira GS Jr, Castro-Alves LJ, Ahmad S, et al. Dexamethasone to prevent postoperative nausea and vomiting: an updated meta-analysis of randomized controlled trials. Anesth Analg 2013; 116:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/29\">",
"      Karanicolas PJ, Smith SE, Kanbur B, et al. The impact of prophylactic dexamethasone on nausea and vomiting after laparoscopic cholecystectomy: a systematic review and meta-analysis. Ann Surg 2008; 248:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/30\">",
"      Kotelko DM, Rottman RL, Wright WC, et al. Transdermal scopolamine decreases nausea and vomiting following cesarean section in patients receiving epidural morphine. Anesthesiology 1989; 71:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/31\">",
"      Bailey PL, Streisand JB, Pace NL, et al. Transdermal scopolamine reduces nausea and vomiting after outpatient laparoscopy. Anesthesiology 1990; 72:977.",
"     </a>",
"    </li>",
"    <li>",
"     Emend (Aprepitant) Prescribing Information. Section 2. Dosage and Administration, 2.2 Prevention of postoperative nausea and vomiting (PONV). file://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf (Accessed on October 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/33\">",
"      Maharaj CH, Kallam SR, Malik A, et al. Preoperative intravenous fluid therapy decreases postoperative nausea and pain in high risk patients. Anesth Analg 2005; 100:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/34\">",
"      Yogendran S, Asokumar B, Cheng DC, Chung F. A prospective randomized double-blinded study of the effect of intravenous fluid therapy on adverse outcomes on outpatient surgery. Anesth Analg 1995; 80:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/35\">",
"      Lee A, Done ML. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: a meta-analysis. Anesth Analg 1999; 88:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/36\">",
"      Kim YH, Kim KS, Lee HJ, et al. The efficacy of several neuromuscular monitoring modes at the P6 acupuncture point in preventing postoperative nausea and vomiting. Anesth Analg 2011; 112:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/37\">",
"      Larson JD, Gutowski KA, Marcus BC, et al. The effect of electroacustimulation on postoperative nausea, vomiting, and pain in outpatient plastic surgery patients: a prospective, randomized, blinded, clinical trial. Plast Reconstr Surg 2010; 125:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/38\">",
"      Allen TK, Habib AS. P6 stimulation for the prevention of nausea and vomiting associated with cesarean delivery under neuraxial anesthesia: a systematic review of randomized controlled trials. Anesth Analg 2008; 107:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/39\">",
"      Greif R, Laciny S, Rapf B, et al. Supplemental oxygen reduces the incidence of postoperative nausea and vomiting. Anesthesiology 1999; 91:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/40\">",
"      Orhan-Sungur M, Kranke P, Sessler D, Apfel CC. Does supplemental oxygen reduce postoperative nausea and vomiting? A meta-analysis of randomized controlled trials. Anesth Analg 2008; 106:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/41\">",
"      Carlisle JB, Stevenson CA. Drugs for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev 2006; :CD004125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/42\">",
"      Apfel CC, Zhang K, George E, et al. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. Clin Ther 2010; 32:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/43\">",
"      Gan TJ, Sinha AC, Kovac AL, et al. A randomized, double-blind, multicenter trial comparing transdermal scopolamine plus ondansetron to ondansetron alone for the prevention of postoperative nausea and vomiting in the outpatient setting. Anesth Analg 2009; 108:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/44\">",
"      Diemunsch P, Schoeffler P, Bryssine B, et al. Antiemetic activity of the NK1 receptor antagonist GR205171 in the treatment of established postoperative nausea and vomiting after major gynaecological surgery. Br J Anaesth 1999; 82:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/45\">",
"      Gan TJ, Gu J, Singla N, et al. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. Anesth Analg 2011; 112:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/46\">",
"      Altorjay A, Melson T, Chinachoit T, et al. Casopitant and ondansetron for postoperative nausea and vomiting prevention in women at high risk for emesis: a phase 3 study. Arch Surg 2011; 146:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/47\">",
"      Singla NK, Singla SK, Chung F, et al. Phase II study to evaluate the safety and efficacy of the oral neurokinin-1 receptor antagonist casopitant (GW679769) administered with ondansetron for the prevention of postoperative and postdischarge nausea and vomiting in high-risk patients. Anesthesiology 2010; 113:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/48\">",
"      Kovac AL, Eberhart L, Kotarski J, et al. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg 2008; 107:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/49\">",
"      Gan TJ, Apfel CC, Kovac A, et al. A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. Anesth Analg 2007; 104:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/50\">",
"      G&oacute;mez-Arnau JI, Aguilar JL, Bovaira P, et al. [Postoperative nausea and vomiting and opioid-induced nausea and vomiting: guidelines for prevention and treatment]. Rev Esp Anestesiol Reanim 2010; 57:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/51\">",
"      Taff RH. Pulmonary edema following naloxone administration in a patient without heart disease. Anesthesiology 1983; 59:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/52\">",
"      Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/53\">",
"      Rose DK, Cohen MM, DeBoer DP. Cardiovascular events in the postanesthesia care unit: contribution of risk factors. Anesthesiology 1996; 84:772.",
"     </a>",
"    </li>",
"    <li>",
"     SCIP-Inf-7 www.qualitynet.org (Accessed on March 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/55\">",
"      Good KK, Verble JA, Secrest J, Norwood BR. Postoperative hypothermia--the chilling consequences. AORN J 2006; 83:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/56\">",
"      Keaney A, Diviney D, Harte S, Lyons B. Postoperative behavioral changes following anesthesia with sevoflurane. Paediatr Anaesth 2004; 14:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/57\">",
"      Bitsch M, Foss N, Kristensen B, Kehlet H. Pathogenesis of and management strategies for postoperative delirium after hip fracture: a review. Acta Orthop Scand 2004; 75:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/58\">",
"      Horlocker TT, Wedel DJ, Benzon H, et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 2003; 28:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/59\">",
"      Baldini G, Bagry H, Aprikian A, Carli F. Postoperative urinary retention: anesthetic and perioperative considerations. Anesthesiology 2009; 110:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/60\">",
"      Stallard S, Prescott S. Postoperative urinary retention in general surgical patients. Br J Surg 1988; 75:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/61\">",
"      Pavlin DJ, Pavlin EG, Gunn HC, et al. Voiding in patients managed with or without ultrasound monitoring of bladder volume after outpatient surgery. Anesth Analg 1999; 89:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/2/33834/abstract/62\">",
"      Ding YY, Sahadevan S, Pang WS, Choo PW. Clinical utility of a portable ultrasound scanner in the measurement of residual urine volume. Singapore Med J 1996; 37:365.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14946 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33834=[""].join("\n");
var outline_f33_2_33834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H154733616\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1324456773\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1271068\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1324456782\">",
"      POSTOPERATIVE NAUSEA/VOMITING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194729369\">",
"      Risk factors for PONV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194727297\">",
"      Pharmacologic agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194727319\">",
"      - Serotonin-receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194727326\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194727333\">",
"      - Anticholinergics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194727340\">",
"      - Neurokinin-receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194727600\">",
"      - Preemptive analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1898562439\">",
"      Other treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194772529\">",
"      Efficacy of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1898562632\">",
"      Approach to therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1898562639\">",
"      - Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1898562646\">",
"      - Rescue therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1275230\">",
"      RESPIRATORY COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154734943\">",
"      Airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H498363751\">",
"      - Pharyngeal muscular weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H498363758\">",
"      - Laryngospasm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194737525\">",
"      - Vocal cord paralysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H498363765\">",
"      - Airway edema",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H498363772\">",
"      - Postoperative cervical hematoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H498363779\">",
"      - Foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154735372\">",
"      Residual effects of anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194742550\">",
"      - Pharmacologic reversal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154735004\">",
"      Compromised oxygen exchange",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194750724\">",
"      Supportive care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1324456938\">",
"      CARDIOVASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1324456945\">",
"      Hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1324456980\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1324456987\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1324457038\">",
"      HYPOTHERMIA OR HYPERTHERMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4139928\">",
"      Hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154733824\">",
"      Shivering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154733840\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H498363842\">",
"      NEUROPSYCHIATRIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154733712\">",
"      Emergence delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154734385\">",
"      Somnolence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154733726\">",
"      Visual disturbance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154733733\">",
"      Epidural hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H154733740\">",
"      Intraoperative awareness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154735179\">",
"      POSTOPERATIVE URINARY RETENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194770753\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H194770760\">",
"      Evaluation and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H154733616\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/14946\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14946|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/18/8494\" title=\"figure 1\">",
"      Simplified PONV risk score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14946|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/41/30364\" title=\"table 1\">",
"      Anti-emetic agents for postoperative nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/36/35405\" title=\"table 2\">",
"      Temperature conversion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/14946|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?35/15/36083\" title=\"waveform 1\">",
"      ECG torsades de pointes and ventricular flutter",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26810?source=related_link\">",
"      Acute traumatic spinal cord injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36068?source=related_link\">",
"      Advanced emergency airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=related_link\">",
"      Awareness with recall following general anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/34/23079?source=related_link\">",
"      Basic airway management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/48/19208?source=related_link\">",
"      Characteristics of antiemetic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/50/34600?source=related_link\">",
"      Corneal abrasions and corneal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/11/15545?source=related_link\">",
"      Endotracheal tube management and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/7/34935?source=related_link\">",
"      Maintenance and replacement fluid therapy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/45/29402?source=related_link\">",
"      Management of cardiac risk for noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31288?source=related_link\">",
"      Neuromuscular blocking agents (NMBA) for rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/61/20442?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/5/28758?source=related_link\">",
"      Opioid withdrawal in the emergency setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11434?source=related_link\">",
"      Overview of the management of postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/42/11945?source=related_link\">",
"      Overview of tracheostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/61/40920?source=related_link\">",
"      Pain control in the critically ill adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/0/18440?source=related_link\">",
"      Perioperative heart failure in noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/17/33046?source=related_link\">",
"      Perioperative management of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29975?source=related_link\">",
"      Perioperative myocardial infarction after noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35943?source=related_link\">",
"      Posterior ischemic optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19178?source=related_link\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21465?source=related_link\">",
"      Temporary cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_2_33835="TIGARO classification";
var content_f33_2_33835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologic risk factors associated with chronic pancreatitis; TIGARO classification",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         T",
"        </strong>",
"        oxic/Metabolic",
"       </td>",
"       <td>",
"        Alcohol, Smoking, Hypercalcemia, Hyperlipidemia, Chronic renal failure, Medication (eg, phenacetin), Toxin (organotin compounds)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         I",
"        </strong>",
"        diopathic",
"       </td>",
"       <td>",
"        Early onset, Late onset, Tropical, or Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         G",
"        </strong>",
"        enetic",
"       </td>",
"       <td>",
"        Cationic trypsinogen (autosomal dominant and recessive), CFTR mutation, SPINK-1 mutation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         A",
"        </strong>",
"        utoimmune",
"       </td>",
"       <td>",
"        Isolated autoimmune chronic pancreatitis, Syndromic (Sjogren, inflammatory bowel disease, primary biliary cirrhosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         R",
"        </strong>",
"        ecurrent acute",
"       </td>",
"       <td>",
"        Post-necrotic, Recurrent acute pancreatitis, Vascular/ischemic disease; Post-irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         O",
"        </strong>",
"        bstructive",
"       </td>",
"       <td>",
"        Pancreatic divisum, Sphincter of Oddi disorders, Duct obstruction (tumor, injury)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001; 120:682.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33835=[""].join("\n");
var outline_f33_2_33835=null;
var title_f33_2_33836="High fiber diet guidelines A";
var content_f33_2_33836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    High fiber diet guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Why we need fiber",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fiber helps children and adults have regular bowel movements and helps prevent constipation and other health problems. Dietary fiber helps keep the bowel and digestive tract healthy and enhances feelings of fullness after eating.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       How much fiber is needed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The recommended intake for dietary fiber is 14 grams/1000 kcals in the diet.* For children, this translates to an intake of about 20 grams/day in early childhood, rising to 29 grams/day for adolescent girls and young women, and 38 grams/day for adolescent boys and young men. To find out the number of grams of fiber in a certain food, read the label, or see the foods listed in this table. High fiber foods contain 3 or more grams of fiber per serving.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       How to help your child eat more fiber",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       A high fiber diet should be a balanced diet with foods fromall the food groups. The most common sources of fiber are whole grain breads and cereals, legumes and nuts, fruits, and vegetables. Include these in your child's balanced diet:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Offer your child a variety of high fiber foods during the day rather than giving only one or two high fiber foods.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Mix a high fiber cereal with a cereal your child likes.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Offer fresh fruits with the skin on. Prunes and pears act as natural laxatives.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Offer raw vegetables, such as carrots, jicama, or cherry tomatoes for snacks and with meals. Offer a salad with dark green lettuce each day.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Use whole wheat bread or white bread with added fiber, brown rice, whole wheat crackers, bran muffins, barley, bran cereals, or oatmeal. Use less refined white flour breads, cereals, and other starches.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Offer 4 to 6 ounces of prune, apple, orange, or pear juice each day. Remember that fresh fruit has more fiber than juice.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Offer snacks that have fiber, like granola bars, fruit bars, fig cookies, or popcorn (after age 3 years).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Help you child develop a taste for bran. Try to include 2 to 4 tablespoons of some form of bran each day.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Add nuts or seeds to breads and salads, or use them as a snack. This is not recommended for children younger than three years.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Preventing constipation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If your child is constipated, follow the dietary guidelines above. Also, encourage your child to drink at least 4 to 8 cups (32 to 64 ounces) of fluid per day, preferably water, low-fat milk, and low-sugar decaffeinated beverages.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    These guidelines are continued.",
"    <div class=\"footnotes\">",
"     * Dietary Guidelines for Americans 2005. US Department of Health and Human Services. Available at: www.health.gov/dietaryguidelines/pubs.htm.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33836=[""].join("\n");
var outline_f33_2_33836=null;
var title_f33_2_33837="Bulbar signs symptoms ALS";
var content_f33_2_33837=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bulbar signs and symptoms associated with amyotrophic lateral sclerosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Upper motor neuron signs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased jaw reflex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Jaw spasticity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Facial diparesis (may be asymmetric)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased facial reflexes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Palmomental sign",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Poor palatal elevation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Slow tongue movement",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lower motor neuron signs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Weak masseter and or pterygoids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Difficulty maintaining jaw closure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Facial diparesis (may be asymmetric)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Poor palatal elevation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tongue weakness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Muscle atrophy and fasciculations",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Upper motor neuron symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Jaw stiffness with difficulty opening the mouth",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Spontaneous clenching or biting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Trismus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spontaneous jaw clonus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Dysphagia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tongue incoordination disrupts the oral phase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pharyngeal muscle incoordination disrupts the pharyngeal phase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Dysarthria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Labial, lingual and/or pharyngeal components",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Spastic with slow, strained speech",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Laryngospasm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Often triggered by secretions (eg, saliva) or food particles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Rapid onset",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            \"Squeezing\" feeling, inability to speak, strained speech",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Short-lived, less than 30 seconds",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Pseudobulbar affect",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Inappropriate laughing, crying, and/or yawning",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Affective response &gt;&gt; emotional trigger",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Mood incongruent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sialorrhea (drooling)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Difficulty managing pharyngeal secretions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Lower motor neuron symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Incomplete eye closure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Difficulty opening and/or closing the jaw",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Difficulty chewing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Disarticulation of the temporomandibular joint when severe",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Poor lip closure and seal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            May contribute to sialorrhea when severe",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Dysphagia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Tongue weakness disrupts the oral phase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Pharyngeal muscle weakness disrupts the pharyngeal phase",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Coughing and choking induced by drinking, eating or saliva secretion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Often thin liquids followed by solids and thick liquids",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Dysarthria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Labial, lingual and/or pharyngeal components",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Slurred, nasal and/or hoarse speech",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hoarseness",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33837=[""].join("\n");
var outline_f33_2_33837=null;
var title_f33_2_33838="Early ST segment shifts after thrombolysis predict outcome";
var content_f33_2_33838=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early ST segment shifts after thrombolysis predict outcome after MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 458px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 734 patients in GUSTO-I, 243 patients had a new ST segment shift 6 to 24 hours after thrombolytic therapy; these patients had a higher 30-day and one-year mortality compared to patients without ST segment changes (upper panel). The duration of the ST segment shift (bottom panel) was also related to the one-year mortality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Langer, A, Krucoff, MW, Klootwijk, P, et al, for the GUSTO-1 ECG Monitoring Substudy Group, J Am Coll Cardiol 1998; 31:783.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33838=[""].join("\n");
var outline_f33_2_33838=null;
var title_f33_2_33839="Eosinophilic folliculitis B";
var content_f33_2_33839=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eosinophilic folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HIV-associated eosinophilic folliculitis is characterized by recurrent, pruritic crops of discrete, erythematous, urticarial follicular papules and rare pustules, with a diameter of 3 to 5 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Toby Maurer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_2_33839=[""].join("\n");
var outline_f33_2_33839=null;
